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ABSTRACT 
Parkinson´s disease (PD) is a debilitating age-related neurological disorder that affects 
various motor skills and can lead to a loss of cognitive functions. The motor symptoms are 
the result of the progressive degeneration of dopaminergic neurons within the substantia 
nigra. The factors that influence the pathogenesis and the progression of the 
neurodegeneration remain mostly unclear. 
This study investigated the role of various programmed cell death (PCD) pathways, 
oxidative stress, and glial cells both in dopaminergic neurodegeneration and in the protective 
action of various drugs. To this end, we exposed dopaminergic neuroblastoma cells (SH-
SY5Y cells) to 6-OHDA, which produces oxidative stress and activates various PCD 
modalities that result in neuronal degeneration. Additionally, to explore the role of glia, we 
prepared rat midbrain primary mixed-cell cultures containing both neurons and glial cell 
types  such  as  microglia  and  astroglia  and  then  exposed  the  cultures  to  either  MPP+ or 
lipopolysaccharide. Our results revealed that 6-OHDA activated several PCD pathways 
including apoptosis, autophagic stress, lysosomal membrane permeabilization, and perhaps 
paraptosis in SH-SY5Y cells. Furthermore, we found that minocycline protected SH-SY5Y 
cells from 6-OHDA by inhibiting both apoptotic and non-apoptotic PCD modalities. We also 
observed an inconsistent neuroprotective effect of various dietary anti-oxidant compounds 
against 6-OHDA toxicity in vitro in SH-SY5Y cells. Specifically, quercetin and curcumin 
exerted neuroprotection only within a narrow concentration range and a limited time frame, 
whereas resveratrol and epigallocatechin 3-gallate provided no protection whatsoever. Lastly, 
we found that molecules such as amantadine may delay or even halt the neurodegeneration in 
primary cell cultures by inhibiting the release of neurotoxic factors from overactivated 
microglia and by enhancing the pro-survival actions of astroglia. 
Together these data suggest that the strategy of dampening oxidative species with 
anti-oxidants is less effective than preventing the production of toxic factors such as 
oxidative and pro-inflammatory molecules by pathologically activated microglia. This would 
subsequently prevent the activation of various PCD modalities that cause neuronal 
degeneration.  
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1. INTRODUCTION 
Parkinson´s disease (PD) is an age-related neurodegenerative disorder that affects 
about 1% of people over 60 years of age and places a significant burden in society, 
particularly in light of increasing life expectancy (Lees et al., 2009). The primary motor 
symptoms of PD, such as resting tremor, rigidity, posture disability, and bradykinesia are the 
result of the degeneration of dopaminergic neurons within the substantia nigra (SN). 
Although the current treatments improve the motor symptoms, fail to prevent the progressive 
loss of neurons. Thus, understanding the mechanism by which these neurons die may shed 
light on the pathogenesis of PD. 
Several lines of evidence have revealed the presence of dopaminergic neurons dying 
through apoptosis, the best-characterized form of programmed cell death (PCD), in 
postmortem PD brains (Anglade et al., 1997; Mochizuki et al., 1996). However, whether 
apoptosis is the primary mode of cell death in PD remains controversial (Tatton et al., 2003). 
Because apoptosis is intimately connected to other, less-characterized forms of PCD, such as 
autophagy and programmed necrosis, these cell death modalities may also play a role in the 
physiopathology of PD. 
Aside from the modality, one of the most important factors that likely cause neuronal 
death in PD is oxidative stress. Thus, several antioxidants (including dietary compounds) 
have been tested in both preclinical and clinical studies. Some of the most studied dietary 
molecules, such as quercetin, resveratrol, epigallocatechin gallate, and curcumin, exhibit 
neuroprotective properties in several in vitro and in vivo models of PD (Kelsey et al., 2010). 
However, the high doses that were used in these studies—considering the markedly limited 
oral bioavailability of these compounds—combined with the low biological activity of their 
metabolites, fail to adequately explain the hypothesized neuroprotective properties of foods 
containing antioxidant molecules (Lambert et al., 2007; Ossola et al., 2009; Walle, 2011). 
Recent evidence has suggested that inhibiting the source of oxidative stress seems 
more promising than using antioxidants. Microglia, the resident inflammatory cells of the 
brain, are the primary source of oxidative species during an inflammatory response by 
activating NADPH oxidase. Interestingly, the inflammatory process that results from the 
activation of microglia has been tightly linked to progressive neurodegeneration in several 
animal models of PD and even in PD patients (Block et al., 2007). Therefore, modulating the 
activation of microglia (e.g., by inhibiting NADPH oxidase) might delay or even stop the loss 
of neurons in PD. 
This thesis investigates the presence of non-apoptotic programmed cell death 
modalities that are induced by 6-hydroxydopamine (6-OHDA), the most frequently used 
toxin for modeling dopaminergic neurodegeneration. Moreover, we tested minocycline and 
several dietary compounds for their putative antioxidant and neuroprotective properties in 
dopaminergic cells that were challenged with 6-OHDA. Lastly, we examined the 
neuroprotective potential of inhibiting the activation of microglia and promoting the release 
of pro-survival factors from astroglia with amantadine in various midbrain primary cell 
cultures.  
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2. REVIEW OF THE LITERATURE 
 
2.1.  Parkinson´s disease (PD) overview 
In 1817, James Parkinson described a previously unknown motor disorder that he 
called “shaking palsy” and that was later renamed Parkinson´s disease (PD) (Parkinson, 
2002). As James Parkinson described in his essay, patients afflicted with this disease display 
“involuntary tremulous motion, with lessened muscular power, in parts not in action and even 
when supported; with a propensity to bend the trunk forwards”. In the late stages of the 
disease, additional neurological disorders, such as depression and dementia, often occur (Lees 
et al., 2009). PD is undoubtedly an age-associated disease, with a prevalence of 0.3% of the 
entire industrialized population, and the incidence increases to 1% and 4% in people over 60 
and 80 years of age, respectively (de Lau and Breteler, 2006). 
The main neuropathological hallmark of PD is a loss of dopaminergic neuromelanin-
containing neurons in the SN pars compacta, which results in a reduction of dopamine 
content in the dorsal part of the striatum (STR). Approximately 3-4% of nigral neurons 
contain inclusions called Lewy bodies (which are primarily in the soma) and Lewy neurites 
(which are in the axon and dendrites) (Lees et al., 2009). Lewy bodies are also present in non-
dopaminergic neurons and even in non-neuronal cells such as astroglia. The primary 
component of these inclusions is alpha-synuclein (?-syn), the mutated forms of which have 
been associated to familial PD. 
The etiology of PD remains unclear. However, both genetic and environmental 
elements are high risk factors. Several genes have been associated with familial cases of PD, 
with ?-syn, parkin, PINK1, LRRK2, and DJ-1 being among the most highly represented. 
However, familial cases of PD represent only 10% of the total patient population and often 
present with clinical features that differ from the typical PD patient, including a relatively 
young onset, dystonia, and early dementia (de Lau and Breteler, 2006). The majority of PD 
cases are sporadic, and several epidemiology studies have associated environmental toxins 
(especially pesticides such as rotenone and paraquat) with a high risk of PD.  
 
2.1.1. Experimental models of PD 
Because the principal pathological hallmark of PD is a loss of dopaminergic neurons 
in the SN, virtually every animal model targets this cell population using various toxins. For 
example, intranigral injection of 6-OHDA, a dopamine analogue, was the first animal model 
that demonstrated the selective loss of dopaminergic neurons (Ungerstedt, 1968). The 
second-most commonly used toxin that causes parkinsonism in both animal models and 
humans is 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Drug addicts who 
erroneously have taken MPTP have developed severe parkinsonism, and Burns and 
colleagues (1983) showed that MPTP intoxication is a suitable model of PD motor symptoms 
in animals. More recently, researchers have reported that pesticides that are associated with 
an increased risk of PD (such as rotenone and paraquat) cause nigral dopaminergic 
neurodegeneration with PD-like movement impairment in rodents (Betarbet et al., 2000; 
McCormack et al., 2002). Moreover, intranigral infusion of lipopolysaccharide (LPS), a 
component of the outer membrane of gram-negative bacteria, evokes a selective 
dopaminergic neurodegeneration in the SN of rodents (Castano et al., 1998). Although all of 
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these models cause a rather selective loss of nigral dopaminergic neurons, they act acutely 
(within a few weeks) and thereby fail to accurately represent the delayed and progressive 
nature of the disease. These cardinal clinical features of PD can be achieved by systemic 
injections of LPS in adult mice, which results in selective, delayed (by several months), and 
progressive (over several months) neurodegeneration (see section 2.5.3) (Qin et al., 2007). 
Interestingly, this systemic LPS neuronal toxicity is exacerbated in mice overexpressing a 
mutant form of human ?-syn (with an A53T missense mutation), highlighting the interaction 
between environmental and genetic factors both in this model and in the disease itself (Gao et 
al., 2011a). 
In addition to toxin-based models, researchers have generated transgenic mice that are 
based on some of the mutated genes that cause familial PD in humans. Specifically, ?-syn 
and LRRK2 (which are dominantly inherited mutated genes) have been either overexpressed 
or knocked out, and Parkin, DJ-1, and PINK1 (which are recessively inherited mutated genes) 
have been knocked out. Unfortunately, although some of these transgenic animals show some 
pathological features of PD, such as ?-syn inclusions, they largely fail to display clear nigral 
dopaminergic neurodegeneration (Gao and Hong, 2011). On the other hand, researchers 
generated a transgenic mouse line called MitoPark that has genetically impaired ATP 
production in midbrain dopaminergic neurons—rather than targeting genes that are associated 
with PD—and exhibits a progressive behavioral and neuropathological PD-like phenotype 
(Ekstrand et al., 2007).  
Although animal models represent a fundamental preclinical step toward developing 
new therapies, to understand the basic cellular and molecular mechanisms of new drugs or 
toxins (and even gene functions), researchers have increasingly been using various cell 
culture systems. For example, primary mesencephalic cultures that contain both neurons 
(including dopaminergic neurons) and glial cells are an ideal tool for studying the direct 
action of drugs on these different cell types and on the cross-talk between the cells. 
Additionally, immortalized neuronal cell lines are particularly suitable for investigating the 
molecular mechanism of action of drugs as well as the function of either wild-type or mutated 
genes because they are highly amenable to genetic manipulation. 
 
2.2. Classification of cell death 
Both in vitro and in vivo,  cells  can  die  through  various  modalities  that  are  defined  
primarily based on morphological criteria rather than by clear biomolecular markers. First, a 
cell is defined as “dead” when any of the following events occurs: i) the plasma membrane is 
damaged, ii) the nucleus undergoes fragmentation into discrete bodies, and/or iii) the cell is 
engulfed by another cell (Kroemer et al., 2009). To date, only four modalities of cell death 
have been sufficiently characterized and include apoptosis, autophagy, cornification, and 
necrosis, which by no means exclude a cell death with mixed features (Kroemer et al., 2009). 
Additionally, the inhibition of one cell death modality often unmasks or facilitates a 
secondary modality. For example, blocking apoptosis with specific inhibitors often merely 
delays cell death and triggers a morphological switch that more closely resembles either 
autophagy or necrosis (Maiuri et al., 2007). Because cornification is a form of cell death that 
occurs exclusively in cells in the epidermis, in the following sections I will discuss only 
apoptosis, autophagy, necrosis, and a less characterized cell death modality called paraptosis. 
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2.2.1. Apoptosis 
Kerr and colleagues (1972) used the term “apoptosis” (from the Greek: falling off of 
leaves) to describe a form of programmed and active cell death that is morphologically 
distinguishable from necrosis. For example, apoptotic cells undergo rounding-up, cellular 
shrinkage, nuclear fragmentation, chromatin condensation, plasma membrane blebbing 
(apoptotic bodies), and (in vivo) engulfment by resident phagocytes without activating an 
inflammatory response (Kroemer et al., 2009). The key players in this type of programmed 
cell death are caspases, a family of cysteine-dependent aspartate-directed proteases that 
activate in a cascade leading to apoptotic cell death (Danial and Korsmeyer, 2004). 
Measuring DNA fragmentation or condensation in conjunction with measuring caspase 
activation is considered the most reliable method for identifying apoptotic cells (Kroemer et 
al., 2009). 
Importantly, a cell death pathway that is morphologically similar to apoptosis may 
occur in the absence of caspase activation. For instance, apoptosis-inducing factor (AIF) can 
be released after permeabilization of the mitochondrial outer membrane and can then 
translocate to the nucleus, where it causes chromatin condensation and subsequent cell death 
in a caspase-independent manner (Susin et al., 1999). However, Leist and Jäätelä (Leist and 
Jäättelä, 2001) suggested a general guideline to morphologically distinguish caspase-
dependent from AIF-induced chromatin condensation. 
 
2.2.2. Autophagic cell death 
Macroautophagy—hereafter referred to as autophagy (from the Greek for “self-
eating”)—is a bulk catabolic process wherein long-lived proteins and organelles are engulfed 
by autophagosomes (double-membrane vacuoles) and digested by fusion with lysosomes. 
Morphologically, autophagy lacks chromatin condensation, exhibits a massive accumulation 
of autophagosomes, and (in vivo) evokes little or no uptake by phagocytes (Ravikumar et al., 
2010). Klionsky and colleagues (2008) provided a comprehensive set of guidelines for 
quantifying autophagy and emphasized the measurement of total autophagic flux rather than 
merely counting the number of autophagosomes. In fact, an increase in the number of 
autophagosomes may paradoxically result from an inhibition of autophagic catabolism if their 
clearance is impaired, for example, by reduced fusion with lysosomes. Autophagy is 
commonly inhibited pharmacologically by 3-methyladenine (3-MA), which blocks the early 
stage of autophagosome formation (Canu et al., 2005; Seglen and Gordon, 1982), whereas 
rapamycin activates autophagy by inhibiting its mammalian target mTOR (Ravikumar et al., 
2010). It is worth noting that the term “autophagic cell death” simply implies dying cells in 
the presence of autophagy rather than autophagy-induced cell death. In fact, at present, 
almost no evidence supports a toxic role of autophagy in eukaryotic cells in vivo, whereas 
autophagy is widely recognized as being cytoprotective in several pathological conditions 
such as neurodegeneration (Garcia-Arencibia et al., 2010). On the other hand, whether a 
direct increase in autophagy induction would result in cytoprotection in every condition is a 
subject of controversy. For example, overexpression of ?-syn (and in particular the A53T 
mutant) induces an increase in mitochondrial autophagy that causes primary cell cultures to 
die and is prevented by genetically blocking the autophagy machinery (Choubey et al., 2011). 
Therefore, it is likely that both the balance between the formation and clearance of 
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autophagosomes and the balance between degraded and synthesized proteins and organelles 
determines whether the outcome will be beneficial or detrimental (Cherra and Chu, 2008). 
Interestingly, several studies found cross-talk between autophagy and apoptosis, which 
suggests a critical interplay between these two pathways in the cell survival destiny in both 
physiological and pathological conditions (Fig.1) (Maiuri et al., 2007). 
 
2.2.3. Necrosis 
Necrosis is generally considered to be an accidental and uncontrolled form of cell 
death that is induced by non-physiological insults such as toxins or physical injury. 
Morphologically, necrotic cells exhibit organellar swelling (especially of mitochondria) and 
an early loss of plasma membrane integrity that evokes an inflammatory response. Often, the 
exclusion of either autophagic or apoptotic markers (e.g., autophagosomes, nuclear 
condensation, and caspase activation) allows for the identification of necrotic cell death. 
However, in recent years, researchers in the field of cell death are beginning to define a form 
of necrosis that is both programmed and tightly regulated, which is mostly associated with a 
pathological cell death (Galluzzi and Kroemer, 2008). This new view of necrosis began when 
Degterev and colleagues (Degterev et al., 2005) named necroptosis a non-apoptotic death that 
is selectively inhibited by necrostatin-1, which was subsequently identified as an inhibitor of 
receptor-interacting serine/threonine-protein kinase 1 (RIP1) (Degterev et al., 2008). To date, 
several molecules and cell processes have been linked to programmed necrosis, with the RIP 
kinase family being the core proteins that are involved in the switch between apoptosis and 
necrosis (Fig.1) (Galluzzi et al., 2009; Zhang et al., 2009b). As described above for apoptosis 
and autophagy, there is also a clear interplay between apoptosis and programmed necrosis, 
wherein the activation of apoptosis appears to suppress the activation of a programmed 
necrotic cell death (Galluzzi et al., 2009). 
 
2.2.4. Paraptosis as an additional PCD modality 
In addition to the cell death modalities that were described above, there are others that 
are not yet well-characterize and therefore not well defined. One example is paraptosis, a 
term that was coined by Bredesen´s group to define a form of non-apoptotic cell death that is 
caused by the overexpression of the insulin-like growth factor I receptor (IGFIR) in several 
cell types (Sperandio et al., 2000). IGFIR-induced cell death is programmed, as it can be 
blocked by inhibiting de novo protein synthesis with cycloheximide (CHX). Moreover, pan-
caspase inhibitors such as zVAD.fmk and BAF fail to suppress IGFIR-induced cell death, 
suggesting that it is distinct from classic apoptotic death. Paraptotic cells exhibit 
mitochondrial swelling and marked cytoplasmic vacuolization that differ from 
autophagosomes, whereas they lack nuclear fragmentation, apoptotic bodies, and show little 
chromatin condensation (Sperandio et al., 2000). Interestingly, these morphological features 
were recently described both in a neurodegeneration model that is caused by amyloid 
precursor protein in mice (Pehar et al., 2010), in neuronal development, and in 
neurodegeneration studies (Sperandio et al., 2000). The activation of either Jun N-terminal 
kinase or extracellular signal-regulated kinase1/2 (ERK1/2)—and ERK2 in particular—play a 
pivotal role in paraptosis, as their inhibition increases cell survival (Sperandio et al., 2000). 
Recently, Bredesen´s group identified two endogenous inhibitors of paraptosis, called 
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AIP/Alix, that interact with the cell death-related calcium-binding protein ALG-2 and 
phosphatidylethanolamine-binding protein (Sperandio et al., 2000; Sperandio et al., 2010). 
 
2.2.5. Mitochondria and lysosomes: converging points of different PCD 
modalities 
Mitochondrial membrane permeabilization (MMP) and the subsequent release of pro-
apoptotic factors (e.g., cytochrome c, Smac/DIABLO, and ATP) have often been described as 
the point of no return in the apoptotic pathway. To date, a growing body of evidence has 
linked  MMP with  other  forms  of  cell  death  such  as  necrosis,  leading  to  the  hypothesis  that  
this point of convergence is when a cell decides which programmed cell death pathway to 
follow (Fig. 1) (Galluzzi and Kroemer, 2008; Galluzzi et al., 2009). 
Lysosomes  are  single-membrane  cytoplasmic  organelles  that  use  their  low  pH  (3.8-
5.0) and wide variety of resident proteases to digest material that is transported by endosomes 
and autophagosomes. Among these proteases, cysteine cathepsins (and particularly 
cathepsins B, C, D and L) are considered critical in lysosomal membrane permeabilization 
(LMP)-induced cell death, as they remain active even at cytosolic pH (Kroemer and Jäättelä, 
2005). Genetic and pharmacologic studies have linked the leakage of these proteases from 
lysosomes with both apoptosis and necrosis (Boya and Kroemer, 2008). For example, LMP 
has been found both upstream and downstream of MMP, thereby leading to either caspase-
dependent or independent cell death (Fig.1) (Boya and Kroemer, 2008). Several studies 
reported the presence of endogenous inhibitors of either LMP or cathepsins such as the heat 
shock protein 70 (Hsp70) family and cystatins (e.g., cystatin C), respectively, providing the 
cell with a degree of control over this dangerous process (Boya and Kroemer, 2008; 
Nylandsted et al., 2004). 
 
2.2.6. PCD in PD 
In an effort to shed light on the pathophysiology of PD, researchers have extensively 
studied the modality by which nigral dopaminergic neurons die. Apoptosis may play an 
important role in this degeneration, as it has been observed postmortem in nigral 
dopaminergic neurons in the brains of PD patients (Anglade et al., 1997; Mochizuki et al., 
1996). On the other hand, other groups, including Banati and colleagues (1998), failed to 
detect apoptotic DNA fragmentation, thereby stirring controversy on the subject. The dispute 
revolves  around  two  principal  points,  the  sensitivity  of  the  methods  used  and  an  unclear  
identification of apoptotic cells. Indeed, considering the slow progression of PD, one would 
expect that each day only a few neurons would die and be cleared relatively rapidly, thereby 
making their detection very challenging (Kanazawa, 2001). On the other hand, the sole use of 
DNA fragmentation  (e.g.,  with  a  TUNEL assay)  as  the  apoptotic  marker  may overestimate  
the number of neurons that die by apoptosis, as DNA fragmentation can also occur through 
apoptosis-independent cell death pathways (Tatton et al., 2003). In mice, the genetic ablation 
of pro-apoptotic proteins such as Apaf-1 or Bax prevents MPTP-induced nigral dopaminergic 
neurodegeneration (Mochizuki et al., 2001; Vila et al., 2001). Interestingly, the levels of both 
Bax and active caspase-3 are increased in the SN of PD brains (Tatton, 2000). 
Researchers have also observed autophagic cell death in dopaminergic neurons in the 
SN of PD brains with an increase in the number of autophagic vacuoles (Anglade et al., 
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1997). As mentioned in section 2.2.2, the increase in the number of these intracellular 
structures may result from their reduced elimination hindering the autophagic process. 
Accordingly, genetically impaired autophagy is highly detrimental to the survival of neurons 
within the CNS (Komatsu et al., 2006). Moreover, the autophagic process appears to be 
responsible, at least in part, for the degradation of wild-type ?-syn in neuronal cell lines such 
as SH-SY5Y and PC12 cells (Vogiatzi et al., 2008). However, the overexpression of ?-syn 
increases the autophagic flux resulting in cell death in primary cortical and mesencephalic 
neuronal cell cultures (Choubey et al., 2011). An increasing body of evidence suggests that 
several genes that are associated with familial PD regulate the autophagic machinery at 
different levels. For example, PINK1 and Parkin are pivotal in the autophagic removal of 
damaged neuronal mitochondria, whereas both wild-type and mutated ?-syn interfere with 
the autophagy-regulated activity of potent neuronal pro-survival transcription factors such as 
myocyte enhancer factor 2D (Geisler et al., 2010; Yang et al., 2009). Additionally, toxins that 
are used to model PD, such as paraquat, 6-OHDA, MPP+, and rotenone, can affect the 
autophagic process. Specifically, the prolonged exposure of cells to rotenone impairs their 
autophagic elimination of ?-syn, thereby leading to its accumulation and subsequent cell 
toxicity (Yu et al., 2009). Olso, blocking the induction of autophagy with siRNA prevents 
MPP+-induced toxicity in SH-SY5Y cells (Zhu et al., 2007). On the other hand, inhibiting 
paraquat-induced autophagy causes an accelerated form of cell death that resembles apoptosis 
(Gonzalez-Polo  et  al.,  2007).  Finally,  6-OHDA  causes  translocation  of  ERK1/2  to  the  
mitochondrial membrane, thereby inducing its removal by autophagy in SH-SY5Y cells, 
which suggests an autophagic stress state (Dagda et al., 2008).  
 
 
 
 
 
 
 
 
Figure 1. Cross-talk among various programmed cell death pathways. For clarity some of the intermediate 
steps are not illustrated. Apoptotic pathways (thick arrows): caspase-8 activates executive caspases (caspase-3, 
6, and 7) resulting in a cell death with DNA fragmentation and chromatin condesation, or alternatively, the 
actions of Bcl-2 family (anti-apoptosis: Bcl-2 and Bcl-XL; pro-apoptosis: Bax and Bak) and BH3 only proteins 
(Bim, Bid, Bad, and Hrk) lead to a mitochondial release of factors (Cyt C, Smac/DIABLO, etc.) that activate the 
executive caspases. Apoptotic and autophagic machineries tightly regulate each other through members of the 
Bcl-2 family and autophagic proteins. Apoptosis also inhibits necroptosis through the cleavage of RIP1 by the 
active caspase-8. The integrity of lysosomes is fundamental for the autophagic process due to the clearance of 
autophagosomes. However, several signalling molecules (caspase-8, Bax, Bim, etc.) may cause the leakage of 
lysosomal enzymes (cathepsins) that directely or through mitochondrial interation can induce cell death with 
either apoptotic or necrotic feature. Paraptotic cell death is characterized by a mitochondrial swelling, a minimal 
chromatine condensation, and the absence of DNA fragmentation. Paraptosis is independent of caspases activity 
and is blocked by inhibitors of either de novo protein synthesis or ERK 2. BAF, BOC-Asp-(OMe)-FMK; CHX, 
cycloheximide; NEC-1, necrostatine-1; PepA, pepstatin A.  
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2.3. Oxidative stress: focus on PD 
Oxidative  stress  refers  to  an  imbalance  in  the  redox state  of  a  cell  that  is  caused  by  
either the overproduction or reduced elimination of reactive oxygen species (ROS) and 
reactive nitrogen species (RNS). The primary forms of ROS are superoxide (·O2), hydrogen 
peroxide (H2O2), and hydroxyl radical (·OH), and the primary forms of RNS are nitric oxide 
(·NO), peroxynitrite (ONOO-), nitrogen dioxide (·NO2), and nitrogen peroxide (N2O2). 
Because of their highly reactive nature, excess levels of ROS and RNS cause oxidative 
damage to key cellular components, such as DNA, RNA, lipids, and proteins, thereby 
resulting in toxicity. Under normal conditions, mitochondria are the major cellular source of 
ROS producing ·O2 as a byproduct of the respiratory chain,  particularly in complexes I  and 
III (Liu et al., 2002). The second-most abundant source of ·O2 is NADPH oxidase, which is 
mainly expressed in macrophages and microglia (Block, 2008). The physiological function of 
·O2 is to kill phagocytosed microorganisms, but its overproduction leads to the toxicity of 
brain cells in several disorders such as Alzheimer´s disease (AD) and PD (Block et al., 2007). 
Due to the potential toxicity of ROS and RNS, cells have developed defense mechanisms to 
counteract their oxidative potential and balance the cellular redox state. For example, 
superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GPx), and reduced 
glutathione (GSH) are the primary endogenous antioxidants that convert reactive free radicals 
into less-reactive molecules (Surendran and Rajasankar, 2010). 
For  the  past  several  decades,  oxidative  stress  has  been  considered  to  be  one  of  the  
most important pathogenic factors in PD. The finding that neuromelanin is a byproduct of the 
auto-oxidation of catecholamines led researchers to theorize that dopamine metabolism might 
be responsible for the sensitivity of dopaminergic neurons to oxidative stress (Graham, 1978). 
Postmortem PD brains exhibit several signs of elevated ROS-induced damage within the SN, 
including lipid peroxidation, DNA damage, and protein oxidation (Surendran and Rajasankar, 
2010). Moreover, the SN of PD patients displays a reduced antioxidative capacity, with a low 
content of GPx and GSH (Martin and Teismann, 2009). This brain region also exhibits 
decreased activity of mitochondrial complex I, which suggests that an increase in ROS may 
be caused by dysregulation of the respiratory chain (Schapira et al., 1990). Interestingly, most 
of the toxins that are used to model PD, such as 6-OHDA, MPTP, paraquat, and rotenone, 
have been linked to oxidative stress. Based on the prevailing view, all of these toxins lead to 
increased ROS levels by inhibiting mitochondrial complex I (Abdulwahid Arif and Ahmad 
Khan, 2010). However, researchers have recently claimed that MPTP, paraquat, and rotenone 
can also cause toxicity that is independent of complex I inhibition (Choi et al., 2008) and that 
rotenone may act primarily through the activation of NADPH oxidase in microglia (Gao et 
al., 2003a). 
 
2.4. Dietary compounds as antioxidants 
Due to the marked toxicity of oxidative stress to brain cells, many putative antioxidant 
compounds have been tested in both preclinical and clinical studies. Among these 
antioxidants, dietary compounds have been most extensively studied because of their wide 
presence in daily foods. In the following sections, I will review four of the most commonly 
studied polyphenols in PD models, namely, quercetin, resveratrol, epigallocatechin 3-gallate, 
and curcumin. 
 16 
2.4.1. Quercetin 
Quercetin is a flavonoid polyphenolic compound widely present in many food plants 
and occurs ubiquitously in the standard human diet. As we previously discussed, quercetin 
confers protective properties in several in vitro and in vivo models of neurodegeneration in 
which  oxidative  stress  often  plays  a  pivotal  role  (Ossola  et  al.,  2009).  Recently,  Bournival  
and colleagues (2009) showed that a low concentration of quercetin (0.1 µM) prevented 
MPP+-induced cell loss and apoptosis in PC12 cells, whereas Di Giovanni and colleagues 
(2010) reported that quercetin (at 5-10 µM) inhibited both ?-syn aggregation and ?-syn-
induced toxicity in PC12 cells. However, some essential issues have cast doubts on the 
potential efficacy of quercetin as a neuroprotective compound. Most importantly, quercetin 
(or its glycosides) is completely metabolized after oral administration in humans (Graefe et 
al., 2001), and hence, it is likely that only low levels (? 0.5 µM) of quercetin metabolites 
reach the brain parenchyma (de Boer et al., 2005). Additionally, sulfate and glucuronate 
conjugates of quercetin, which are the main metabolites present in human plasma (Graefe et 
al., 2001), display reduced biological activity compared to the parent form of quercetin 
(Ossola et al., 2009). Lastly, in most studies, quercetin-induced toxicity occurred at 
concentrations that were only two- to five-fold higher than the concentration that confers the 
highest protection, thereby raising concerns regarding its narrow therapeutic window. 
 
2.4.2. Resveratrol 
In “the French paradox”, a moderate consumption of red wine has been associated 
with a decreased risk of cardiovascular disease; despite a high intake of saturated fat (Renaud 
and de Lorgeril, 1992). Resveratrol is a non-flavonoid polyphenolic compound that is 
primarily found in red wines (at a concentration of ~5 mg/L, which equates to ~22 µM), as 
these wines are produced by fermenting grapes in the presence of the skin and seeds (Ribeiro 
de Lima et al., 1999). In humans, a single oral dose of 25 mg of resveratrol results in a 
plasma concentration of about 2 µM, of which only 1% represents the non-metabolized drug 
(Walle, 2011). Resveratrol has been claimed to confer several health benefits, such as cancer 
prevention, cardioprotection, cognitive improvement, and neuroprotection (Albani et al., 
2010; Corder et al., 2001; Dore, 2005; Jang et al., 1997). Several studies investigated the 
neuroprotective properties of resveratrol in both in vitro and in vivo PD models.  One of the 
first studies was conducted by Karlsson and colleagues (2000), who found that resveratrol (at 
? 50 µM) protects embryonic mesencephalic dopaminergic neurons from tert-butyl 
hydroperoxide. Recently, studies have shown that resveratrol prevents both MPP+- and 4-
hydroxynonenal-induced toxicity in PC12 cells at 0.1 and 5 µM, respectively (Bournival et 
al., 2009; Siddiqui et al., 2010). Moreover, 75 µM resveratrol protects SK-N-BE cells from 
both 6-OHDA and the A30P mutant of ?-syn, while 30 µM resveratrol protects dopaminergic 
neurons in slice cultures that are exposed to MPP+ (Albani et al., 2009; Okawara et al., 2007). 
However, Chinta and colleagues (2009) failed to observe protection of N27 cells by paraquat, 
yet they found that resveratrol causes endoplasmic reticulum stress-induced cell death. 
Vauzour and colleagues (2007) warned of the possible creation of a potent neurotoxin when 
resveratrol is metabolized by tyrosinase, which is expressed in high levels within the SN. 
Recently, several groups investigated the putative neuroprotective properties of 
resveratrol in in vivo models of PD. For example, rats receiving resveratrol (20 mg/kg/day by 
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i.v. injection) for one week exhibits resistance to MPTP-induced motor impairment, increased 
ROS, and neuronal loss in the SN (Lu et al., 2008). Moreover, resveratrol prevents 6-OHDA-
induced parkinsonism in various experimental paradigms using rats. Specifically, i.p. 
injection of resveratrol (20 mg/kg/day) for two weeks prior to infusing the toxin prevents 6-
OHDA-induced dopaminergic neuron loss (Khan et al., 2010). In addition, oral 
administration of resveratrol or its liposomal form (20 mg/kg/day) for two weeks prior to 
administering the toxin counteracts 6-OHDA-induced motor complications and apoptosis of 
dopaminergic neurons (Wang et al., 2011). Interestingly, in another study, even post-lesion 
oral administration of resveratrol (10 mg/kg/day) improved the behavior of rats as early as 
within two weeks of treatment (Jin et al., 2008). 
Mechanistically, the most common view of the action of resveratrol involves its direct 
free radical scavenging properties, which causes the reduction of ROS both in vitro and in 
vivo (Karlsson et al., 2000; Lu et al., 2008; Siddiqui et al., 2010; Wang et al., 2011). In 
addition, resveratrol restores endogenous antioxidant systems such as GSH levels and GPx, 
SOD, and CAT activities in rats that were lesioned with 6-OHDA (Khan et al., 2010). 
Interestingly, Robb and colleagues (2008) found that resveratrol increases the basal level and 
activity of the mitochondrial isoform of SOD in intact mice, suggesting that this drug may 
stimulate the endogenous antioxidant system through intracellular signaling. This is 
consistent with the finding that resveratrol increases the protein level of the indirect 
antioxidant enzyme heme oxygenase-1 (HO-1), an indirect antioxidant enzyme, in cortical 
neurons (Sakata et al., 2010; Zhuang et al., 2003). Another attractive intracellular target of 
resveratrol is SIRT1, a NAD+-dependent class III histone deacetylase, which is believed to be 
an evolutionally conserved longevity protein (Herranz and Serrano, 2010; Howitz et al., 
2003). For example, investigators linked the resveratrol-induced increase in the health and 
survival of mice fed a high-calorie diet to the activation of the SIRT1 pathways (Baur et al., 
2006). Moreover, the activation of SIRT1 plays a pivotal role in the protective properties of 
resveratrol against 6-OHDA and ?-syn in SK-N-BE cells (Albani et al., 2009). As discussed 
previously (see section 2.3), microglial NADPH oxidase is a potential neurotoxic source of 
ROS. Thus, it is interesting that resveratrol (at 60 µM) protects dopaminergic neurons in a 
primary culture that was exposed to LPS by inhibiting NADPH oxidase (Zhang et al., 2010). 
Moreover, the beneficial effects of resveratrol may derive from several actions on astroglia, 
such as increases in glutamate uptake, GSH levels, and the release of growth factors 
(Quincozes-Santos and Gottfried, 2011). Additional targets of resveratrol have been 
thoroughly reviewed by Pervaiz and Holme (2009) and include the activation of the PI3-Akt 
pathway and protein kinase C (PKC) as well as the inhibition of pro-apoptotic factors.  
Despite these reports suggesting the neuroprotective properties of resveratrol, the 
relatively high concentration that is required for this effect fails to support the notion that 
consuming foods that are rich in resveratrol may help in PD. In fact, this compound is 
extensively metabolized, and the bioavailability of an oral dose is less than 1%, which most 
likely results in nanomolar concentrations within the organ parenchyma (Walle, 2011). 
Moreover, only 0.03% of an oral dose of 50 mg/kg resveratrol reached the brain parenchyma 
in rats (El Mohsen et al., 2006). However, I cannot exclude that dietary supplementation with 
high doses of an improved delivery formulation of resveratrol might be beneficial in PD. 
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2.4.3. Epigallocatechin 3-gallate (EGCG) 
Epidemiological studies have associated the consumption of tea with a decreased risk 
of  certain  neurological  disorders  such  as  cognitive  impairment  and  PD  (Checkoway  et  al.,  
2002; Hu et al., 2007; Kuriyama et al., 2006). EGCG is the most abundant flavonoid in tea, 
especially green tea containing up to 78 mg of EGCG per 100 ml (about half a cup), which 
equates to 1.7 mM (U.S. Department of Agriculture, 2007). EGCG is considered to be the 
principal molecule that gives tea its beneficial effects, and the consumption of 2 cups of green 
tea (containing approximately 312 mg of EGCG) would likely result in a concentration in 
human plasma in the low micromolar range (? 1 µM), based on an extrapolation of data from 
subjects that received 30 mg of EGCG (Del Rio et al., 2010). Moreover, as is the case with 
most polyphenols, EGCG that is detectable in the plasma after oral administration is mostly 
metabolized (Lambert et al., 2007). Researchers have intensely studied EGCG for its putative 
neuroprotective properties in different neurodegenerative models, including PD. Some in 
vitro studies reported that considerably low concentrations of EGCG (? 0.1 µM) prevent the 
toxicity of either 6-OHDA in SH-SY5Y cells or serum deprivation in PC12 cells (Levites et 
al., 2002; Reznichenko et al., 2005; Wang et al., 2009b). On the other hand, Tai and Truong 
(2010) required higher concentrations of EGCG (? 1 µM) to counteract the toxicity induced 
by  DDT  (a  pesticides  that  has  been  linked  to  PD)  in  SH-SY5Y  cells.  At  similar  
concentrations  (? 1  µM),  EGCG  also  prevents  the  activation  of  primary  microglia-induced  
toxicity of both SH-SY5Y and primary dopaminergic cells (Li et al., 2004). In contrast, Stull 
and colleagues (2002) found that EGCG (at 5 µM) only mildly protects mesencephalic 
dopaminergic cells from MPP+. Several other studies failed to observe protection by EGCG 
from either MPP+ in PC12 and SH-SY5Y cells or rotenone in SH-SY5Y cells (Chung et al., 
2007; Ma et al., 2010; Mazzio et al., 2001). EGCG exhibited neuroprotection in some in vivo 
PD models, especially in the MPTP mouse model. For example, Youdim´s group found that 
oral administration of EGCG (2-20 mg/kg7day, 10 days prior to and during the toxin 
exposure) prevents MPTP-induced toxicity of the dopaminergic system in mice (Levites et 
al., 2001; Mandel et al., 2004). Likewise, Choi and colleagues (2002) confirmed that oral 
administration of EGCG (25 mg/kg7day, only 1 day prior to and during the toxin exposure) 
protects dopaminergic cells in the SN of mice that received MPTP. A recent study revealed 
that EGCG not only prevents death but also markedly rescues Drosophila melanogaster from 
paraquat while reversing the impaired movement caused by the toxin (Jimenez-Del-Rio et al., 
2010). Leaver and colleagues (2009), however, observed only moderately improved behavior 
and no neuroprotection in rats that were unilaterally lesioned with 6-OHDA. In addition to its 
neuroprotective properties, EGCG may improve the symptomatic treatment of PD patients by 
reducing L-DOPA methylation that is caused by catechol-O-methyltransferase (COMT). 
Indeed, Kang and colleagues (2010) demonstrated that EGCG inhibits COMT in vitro (with 
an IC50 of 360 nM) and that its oral administration (at 400 mg/kg) moderately decreases the 
level of 3-O-methyldopa in both plasma and the striatum, while increasing the concentration 
of dopamine only in the striatum. It is worth noting that COMT inhibitors that are currently 
used in the symptomatic treatment of PD block its enzymatic activity with an IC50 of about 1 
nM (Nissinen and Männistö, 2010). 
As with most polyphenols, the common view of the action of EGCG involves its free 
radical scavenging properties and its iron chelating activity (Guo et al., 1996). Similar to 
resveratrol, EGCG may protect against oxidative stress by enhancing endogenous antioxidant 
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defenses, such as SOD and CAT or by reducing the expression of neuronal iNOS, as shown 
in mice (Choi et al., 2002; Levites et al., 2001). In addition to its antioxidative properties, 
Youdim´s group demonstrated that the activation of PKC is crucial for the neuroprotective 
action of EGCG in vitro (Levites et al., 2002; Reznichenko et al., 2005). Additionally, in 
mice, Mandel and colleagues (2004) showed that EGCG increases the level of PKC?. 
Interestingly,  the  activation  of  PKC  by  1  µM  EGCG  in  SH-SY5Y  cells  leads  to  the  
inactivation and proteasomal degradation of Bad, which otherwise would induce 
mitochondrial membrane permeabilization and the subsequent release of pro-apoptotic 
proteins (Kalfon et al., 2007). In addition to its direct action on neurons, EGCG may confer 
neuroprotection by inhibiting the activation of microglia-induced neurodegeneration. For 
example, Li and colleagues (Li et al., 2004) demonstrated that EGCG directly inhibits the 
production of pro-inflammatory factors in primary microglia cultures. Lastly, increasing 
evidence suggests that EGCG detoxifies ?-syn aggregation by potently inhibiting its 
fibrillogenesis and even by remodeling its mature, aggregated form (Bieschke et al., 2010; 
Ehrnhoefer et al., 2008). 
EGCG is likely one of the most potent polyphenols and its high level in green tea may 
yield a concentration that is biologically active in some peripheral tissues. However, brain 
levels of EGCG are likely to be much lower than in the plasma because the metabolites 
(which are the main form of EGCG in plasma) usually cross the blood-brain barrier (BBB) 
more difficultly than the parent compound. 
 
2.4.4. Curcumin 
Curcumin is a polyphenol that is mostly present in the root of the turmeric plant 
(Curcuma longa), which is widely used as a spice in curry mixtures, particularly in Indian 
and Chinese dishes. Phase II and Phase I clinical trials showed that curcumin may improve 
the outcome of pancreatic and breast cancers, respectively, whereas a double-blinded and 
placebo-controlled study failed to find any improvement in AD patients (Baum et al., 2008; 
Bayet-Robert et al., 2010; Dhillon et al., 2008). Several preclinical studies reported 
neuroprotective properties of curcumin in models of PD. For example, relatively low 
concentrations (? 1 µM) of curcumin prevents MPP+ toxicity in both primary dopaminergic 
and SH-SY5Y cells and increases the viability and neurite outgrowth of differentiated PC12 
cells (Ray and Lahiri, 2009; Sawada et al., 2002; Yu et al., 2010). Moreover, curcumin (at 4 
µM) protects SH-SY5Y cells from both ?-syn exposure and over-expression. In addition, 10 
µM curcumin inhibits microglia activation-induced toxicity in primary dopaminergic neurons 
and 6-OHDA toxicity in MES23.5 cells and (at 20 µM) prevents MPP+-induced toxicity in 
PC12 cells (Chen et al., 2006; Lee et al., 2007; Wang et al., 2009a; Wang et al., 2010a; Yang 
et al., 2008). However, Mazzio and colleagues (2001) failed to confirm a protective effect of 
curcumin against MPP+-induced toxicity in PC12 cells. 
Due to its limited oral bioavailability, animal studies of curcumin typically use i.p. as 
the route of administration. Reports using various administration protocols demonstrated that 
curcumin (at 50 or 80 mg/kg/day) protects the dopaminergic system in mice that received 
MPTP and in rats that were unilaterally lesioned with 6-OHDA (Rajeswari and Sabesan, 
2008; Vajragupta et al., 2003; Yu et al., 2010; Zbarsky et al., 2005). Noteworthy, some 
studies reported that curcumin inhibits the enzymes monoamine oxidase (MAO) A and B, 
thereby increasing striatal dopaminergic content in mice (Kulkarni et al., 2008; Rajeswari and 
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Sabesan, 2008; Xu et al., 2005c). Therefore, because MAO-B converts MPTP to its toxic 
metabolite MPP+, inhibiting this enzyme could at least partially explain the protective action 
of curcumin in the MPTP PD model. 
Once again, as a polyphenol, curcumin exerts its free radical scavenging action 
through the marked chelation of iron and copper, both of which have been linked to both AD 
and PD (Baum and Ng, 2004; Sharma et al., 2007). Additionally, curcumin boosts 
endogenous antioxidative defenses by increasing the level of GSH in mice and increases 
GSH efflux from primary astroglia cultures, although the latter effect requires a high 
concentration (30 µM) (Jagatha et al., 2008; Rajeswari and Sabesan, 2008; Stridh et al., 
2010). Additionally, the proteins HO-1 and Hsp70, which are linked to reduced oxidative 
stress, are up-regulated both in vitro and in vivo by curcumin treatment (Calabrese et al., 
2009). Moreover, the inhibition of microglial release of pro-inflammatory factors in vitro and 
the down-regulation of both nuclear factor kappa B (NF-?B, which is involved in 
inflammation) and iNOS both in vitro and in vivo all serve to underscore the putative anti-
inflammatory action of curcumin (Begum et al., 2008; Yang et al., 2008). With regard to 
EGCG, even curcumin appears to potently inhibit ?-syn fibrillogenesis and even destabilize 
preformed ?-syn fibrils, thereby leading to reduced toxicity in PC12 cells (Ono and Yamada, 
2006; Wang et al., 2010a). Lastly, Wang and colleagues (2010b) demonstrated that curcumin 
(at ? 5 µM) increases the viability of cortical neurons by releasing brain-derived neurotrophic 
factor (BDNF) and activating its signal transduction pathway. 
Clinical studies typically require high doses (1-8 g/day) of curcumin, due to its 
markedly limited oral bioavailability, its poor absorption, and its rapid metabolism and 
elimination. For example, oral administration of 4 g/day for 3 months yields less than 2 µM 
in plasma of patients (Cheng et al., 2001). Thus, supplementing one’s diet with curcumin—
even at the levels that are used in India and China— likely fails to achieve biologically active 
concentrations in the human brain. 
 
2.5. The role of glia in PD 
It is generally believed that the adult human brain contains approximately 1011 
neurons and approximately 10 times more glial cells, such as astroglia, microglia, and 
oligodendrocytes. However, this view has been recently challenged by a report showing that 
the adult human brain contains approximately equal numbers of neuronal and non-neuronal 
cells, although this varies widely among various brain regions (Azevedo et al., 2009). Despite 
this ongoing controversy, glial cells undoubtedly play a crucial role in neuronal function in 
both physiological and pathological conditions, including neurodegenerative disorders such 
as PD. In the following sections, I will review the role of microglia and astroglia both in 
normal brain function and in the pathophysiology of PD. 
 
2.5.1. Microglia 
Microglia are the resident macrophages of the CNS and comprise approximately 10-
12% of all cells in an adult brain. In contrast to other glial cell types, microglia are derived 
from the periphery (specifically, from primitive myeloid progenitors that infiltrate and 
differentiate in the CNS during embryogenesis) (Ginhoux et al., 2010). In mice, a low rate of 
local cell division maintains the number of resident microglia in the healthy brain (Ajami et 
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al., 2007). In contrast, in some pathological conditions in which the BBB is compromised, 
peripheral monocytes and leukocytes may infiltrate the CNS and participate in the 
neuroinflammatory process (Rezai-Zadeh et al., 2009). Microglia are not uniformly 
distributed, but have a higher density in gray matter than in white matter and are especially 
prevalent in the hippocampus, basal ganglia, and the SN in mice (Lawson et al., 1990). In 
humans, however, the distribution of microglia appears to be more homogeneous among the 
various subcortical regions, with a higher density in white matter than in gray matter 
(Mittelbronn et al., 2001). Being the resident macrophages, microglia represent the first line 
of defense for the CNS by actively inspecting the surrounding microenvironment, even while 
in the resting state (Nimmerjahn et al., 2005). Upon activation, microglia dramatically shift 
their morphology from a ramified structure to an amoeboid shape with enlarged soma, and 
they upregulate several surface molecules, including chemokine and cytokine receptors (Cho 
et al., 2006; Nimmerjahn et al., 2005). Microglia are exquisitely sensitive pathogenic sensors 
that react extremely rapidly upon the recognition of products derived from microorganisms, 
so-called pathogen-associate molecular-pattern (PAMPs) molecules. Microglia also recognize 
endogenous molecules and debris that could disrupt the brain homeostasis, which are 
generally called damage-associate molecular-pattern (DAMPs) molecules (Rubartelli and 
Lotze, 2007). In addition to detoxification, the clearance of debris by microglia also plays a 
pivotal role in the reorganization and regeneration of the neuronal network (Neumann et al., 
2009). For example, Wake and colleagues (2009) suggested that microglia are responsible for 
remodeling the presynaptic structures of cortical neurons by responding to pathological—and 
even physiological—stimuli. Depending on the cue that they receive from the environmental, 
microglia respond with various degrees of activation, and researchers often differentiate 
activated versus overactivated microglia. This has been studied primarily in peripheral 
macrophages, in which the activated state (called M2) and overactivated state (called M1) are 
considered to be more beneficial or more toxic, respectively (Martinez et al., 2008). 
However, it is more likely that macrophages/microglia exist in a diverse range of forms, each 
of which produces a distinct set of cytokines and expresses a unique complement of cell-
surface receptors (Hanisch and Kettenmann, 2007). These distinct activation states are 
believed to underlie the beneficial and detrimental actions of microglia in several 
neurological disorders, including PD (Hanisch and Kettenmann, 2007). 
 
2.5.2. Evidence of activated microglia in PD 
Interest in the role of neuroinflammation in PD began with the seminal report by 
McGeer and colleagues (1988), who showed for the first time that the SN of the postmortem 
PD brains display a higher content of activated microglia than control brains. Moreover, 
researchers observed higher numbers of activated microglia in the hippocampus of dementia 
patients who were diagnosed pre-mortem with AD or PD. This finding was confirmed by 
other groups for cases of PD or parkinsonian syndrome that were induced by exposure to 
MPTP (Imamura et al., 2003; Langston et al., 1999). Recently, premortem studies in PD 
patients using PET imaging found an increased level of activated microglia in cortical 
regions, in the pons, and in the basal ganglia (Gerhard et al., 2006). In addition, in patients 
with early-stage PD, an increase in activated microglia in the midbrain was negatively 
correlated with the level of dopaminergic terminals in the putamen and positively correlated 
with motor impairment (Ouchi et al., 2005). It is now well recognized that most animal 
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models of PD also exhibit signs of an inflammatory response. For example, MPTP evokes the 
activation  of  microglia  in  both  the  SN  and  STR  of  mice  and  monkeys,  even  5  to  14  years  
after toxicity was induced (Kohutnicka et al., 1998; McGeer et al., 2003). Similarly, Cicchetti 
and colleagues (2002) used PET imaging and immunohistochemistry to revealed that 6-
OHDA increases the number of activated microglia in the SN and STR of rats, and this was 
inversely correlated to the number of dopaminergic neurons in the SN. 
 
2.5.3. The causative link between inflammation and PD 
Although the aforementioned reports support a tight association between the 
degeneration of the nigrostriatal dopaminergic pathway with neuroinflammation in both 
human disease and animal models of PD, investigating the causative link required the use of 
the endotoxin lipopolysaccharide (LPS). LPS is the principal component of the outer 
membrane of gram-negative bacteria and elicits a strong immune response by activating 
monocytes, including macrophages/microglia. Castano and colleagues (1998) were the first to 
report that in vivo dopaminergic neurons in the SN are sensitive to intranigral LPS toxicity. 
Similarly, Gao and colleagues (2002c) showed that a chronic intranigral infusion of LPS 
evokes the selective and progressive loss of dopaminergic neurons within the SN of rats six 
weeks after the infusion. Importantly, researchers observed that the activation of microglia 
precedes the loss of dopaminergic neurons by several weeks, suggesting a causative role of 
the neuroinflammatory response. Moreover, Carvey´s group demonstrated that the 
dopaminergic system is also sensitive to the systemic injection of LPS by prenatally injecting 
mice with the endotoxin and observing a loss of dopaminergic neurons that was accompanied 
by neuroinflammation in the offspring, and this effect lasted up to 16 months (Carvey et al., 
2003; Ling et al., 2002). Recently, Qin and colleagues (2007) revealed that a single systemic 
injection of LPS in two-month old mice induces the degeneration of nigral dopaminergic 
neurons after seven months, and this effect progresses over the following three months. 
Interestingly,  the  systemic  injection  of  LPS  evokes  a  rapid  (within  1  h)  immune  response  
(based on the level of TNF?) that resolves in the periphery (e.g., liver and serum) within a 
few hours, but persists for 10 months in the brain (Qin et al., 2007). This animal study may 
actually  have  clinical  relevance  in  the  etiology  of  PD,  as  exposure  to  LPS  also  induces  a  
parkinsonian syndrome in the presence of chronic neuroinflammation in humans (Niehaus 
and Lange, 2003). Altogether, these data strongly suggest that transient systemic 
inflammation may cause chronic neuroinflammation leading to the delayed and progressive 
degeneration of the dopaminergic systems of both animals and humans. Additionally, pre-
existing  neuroinflammation  (e.g.,  from  prenatal  exposure  to  LPS)  also  sensitizes  central  
dopaminergic neurons to a secondary hit, for example, by environmental toxins, such as 
rotenone or LPS (Ling et al., 2004; Ling et al., 2006). Moreover, intranigral infusion of LPS 
primes microglia and sensitizes dopaminergic neurons to toxic effects of paraquat (Mangano 
and Hayley, 2009). These data support the notion that PD may result from the coordinated 
action of multiple factors, such as a multiple hit of environmental toxins. Gene–environment 
interactions are another example of a multiple-hit  hypothesis that  may lead to PD (Gao and 
Hong, 2011). For example, overexpression of the A53T mutant form of human ?-syn (the 
genetic factor) in mice renders their nigral dopaminergic neurons susceptible to toxicity by 
LPS (the environmental factor) (Gao et al., 2011a). More specifically, the systemic injection 
of LPS at a low dose causes chronic neuroinflammation and subsequent nigral dopaminergic 
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neurodegeneration after 2.5 months in the transgenic mice (but not in wild-type mice). 
Moreover, this degeneration presents an accumulation of nitrated mutant ?-syn aggregation 
and Lewy body-like inclusions that co-localized with dopaminergic neurons in the SN. 
Altogether, these studies revealed that an inflammatory cue—either central or systemic—can 
evoke chronic neuroinflammation that leads to behavioral and anatomical PD-like pathology 
in animals and perhaps even in humans. 
Because of the overwhelming evidence supporting the involvement of 
neuroinflammation in PD in both animal models and humans, researchers have been testing 
anti-inflammatory treatments as potential new therapies. For example, the genetic ablation of 
iNOS in mice renders them more resistant to MPTP-induced neuroinflammation and nigral 
dopaminergic neurodegeneration (Liberatore et al., 1999). Similarly, the simultaneous 
pharmacological inhibition of iNOS and NADPH oxidase reverse the chronic 
neuroinflammation, ?-syn pathology, and neurodegeneration that results from a systemic 
injection of LPS (Gao et al., 2011a). Additionally, genetically ablating either TNF? or its 
receptors, which have a pivotal role in chronic neuroinflammation, protects mice from MPTP 
toxicity (Ferger et al., 2004; Sriram et al., 2002). Interestingly, only by blocking soluble 
TNF? in the SN, but not in the STR, could prevent both 6-OHDA and LPS-induced 
degeneration of dopaminergic neurons, thus highlighting the importance of 
neuroinflammation in the nigral region (McCoy et al., 2006). 
 
2.5.4. How do microglia cause progressive neurodegeneration? 
Microglia represent the principal cells in the CNS carrying out the deleterious effects 
of toxins that evoke neuroinflammation. Bronstein and colleagues (1995) demonstrated that 
LPS fails to directly induce toxicity in dopaminergic neurons but requires the presence of 
microglia. Moreover, even rotenone and paraquat toxicity are likely independent of a direct 
inhibition of neuronal mitochondrial complex I, but rather act primarily through microglia 
activation (Choi et al., 2008). Indeed, concentrations of either rotenone or paraquat that cause 
the death of dopaminergic neurons in neuron-glia mixed cultures (containing neurons, 
astroglia and microglia) fail to evoke toxicity in neuron-enriched cultures (Gao et al., 2002b; 
Wu et al., 2005). Furthermore, these studies revealed that cultured cells become completely 
resistant to either rotenone or paraquat by inhibiting NADPH oxidase-induced ROS. 
MPTP/MPP+ toxicity, in addition to directly affecting dopaminergic neurons, is also partially 
dependent on the activation of microglia. In fact, the presence of microglia enhances 
MPTP/MPP+ toxicity and, more importantly, renders the neurodegeneration progressive (Gao 
et al., 2003b; Gao et al., 2011b). A similar progressive neurodegeneration that is dependent 
on microglia occurs after the application of either LPS or rotenone (Gao et al., 2011b). 
Interestingly, after the initial exposure, washing out LPS and MPP+, fails to stop the immune 
response and progressive neurodegeneration, suggesting the formation of a self-sustaining 
cycle that maintains the activation of microglia (Fig. 2). In this study, the molecule 
responsible (at least partially) for the chronic activation of microglia appears to be high-
mobility group box 1 (HMGB1), an intracellular protein that is released upon neuronal 
degeneration. On the other hand, HMGB1, which is considered a DAMP molecule, can be 
also actively released from a various cell types (e.g. microglia) and its extracellular actions 
seem to result mainly from the binding of receptor for advanced glycation end products 
(RAGE) (Rauvala and Rouhiainen, 2010). Many other proteins, most of them considered 
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DAMPs, that are released from dying dopaminergic neurons activate microglia through the 
binding of an extensive complement of surface receptors called pattern-recognition receptors 
(PRRs), including the toll-like receptor (TLR) family, scavenger receptors, and the 
macrophage antigen complex 1 (MAC1) receptor etc. (Block et al., 2007). For example, 
neuromelanin, a well-characterized marker of human nigral dopaminergic neuron, displays a 
pro-inflammatory phenotype, and its intranigral infusion causes dopaminergic 
neurodegeneration (Wilms et al., 2003; Zecca et al., 2008). Moreover, aggregated ?-syn—in 
particular, the A30P and A53T mutants of human ?-syn— causes selective dopaminergic 
neurodegeneration by activating microglia through the binding of MAC1 receptor (Zhang et 
al., 2005; Zhang et al., 2007). Another intracellular protein that may participate in chronic 
inflammation upon its release is µ-calpain, a calcium-dependent protease that is enriched in 
the SN of PD brains and whose inhibition protects mice from MPTP (Crocker et al., 2003). 
Levesque and colleagues (2010) demonstrated that injured N27 cells (a dopaminergic cell 
line) release µ-calpain, whose activity induces selective dopaminergic cell loss by activating 
microglia. Yet another protein that appears to be involved in self-sustained chronic 
neuroinflammation and progressive neurodegeneration in both AD and PD is matrix 
metalloprotease-3 (MMP-3) (Kim and Hwang, 2011). Specifically, injured dopaminergic 
neurons release an active form of MMP-3 that in turn causes toxicity through microglia 
activation, and MMP-3-/- mice are markedly resistant to MPTP toxicity (Kim et al., 2007). 
Altogether, these studies support the hypothesis that chronic activation of microglia is 
maintained by pro-inflammatory factors released by dying neurons in the diseased brain (Fig. 
2). Alternatively, in a healthy brain, neurons also participate in maintaining microglia in the 
resting state by expressing anti-inflammatory factors. For example, fractalkine (CX3CL1), 
which is constitutively expressed in neurons as a membrane-bound protein, is released upon 
cleavage and decreases the pro-inflammatory activity of microglia by binding to its receptor 
(CX3CR1), which is exclusively expressed in these cells (Zujovic et al., 2000). Accordingly, 
CX3CR1-/- mice are more sensitive to both MPTP- and LPS-induced neuronal toxicity, 
whereas infusing CX3CL1 prevents 6-OHDA-induced dopaminergic neurodegeneration 
(Cardona et al., 2006; Pabon et al., 2011). Additionally, researchers have described several 
neuronal adhesion and recognition molecules, including NCAM, ICAM5, and semaphorins, 
that maintain glial cells in a inactive state (Tian et al., 2009). Therefore, the decrease of these 
anti-inflammatory molecules, due to a loss of neurons in a specific region, results in local 
microglial susceptibility, which may contribute to the formation of chronic 
neuroinflammation and progressive neurodegeneration.  
In summary, the progressive degeneration in PD may start by activated microglia 
causing an initial neuronal injury that in turn induces the release of factors that overactivate 
microglia and boost their neurotoxicity; at the same time, the anti-inflammatory action of 
neurons is reduced due to a reduction in their numbers (Fig. 2). This self-sustained cycle 
would  also  occur  in  the  case  of  a  toxin  such  as  MPTP  and  6-OHDA  that  directly  causes  
neuronal injury, which would then release pro-inflammatory factors, leading to the activation 
of microglia that would participate in the progression of the neurodegeneration (Fig. 2). 
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2.5.5.  Microglia as targets for the treatment of PD: focus on NADPH oxidase 
Due to the strong evidence supporting a role of neuroinflammation in the pathology of 
PD, microglia have received great interest as a possible target in the treatment of this disease. 
Epidemiological studies have reported that the consumption of non-steroidal anti-
inflammatory drugs (NSAIDs) tends to be associated with a decreased risk of developing PD 
(Chen et al., 2003; Ton et al., 2006). However, although no clinical trials have tested NSAIDs 
in PD, this class of drugs produced disappointing results in improving the cognitive 
impairment in AD patients who presented with strong neuroinflammation (Ho et al., 2006; 
McGeer and McGeer, 2007). One criticism of this anti-inflammatory therapy is that NSAIDs, 
which inhibit cyclooxygenase enzymes, block the production of a limited number of pro-
inflammatory factors such as prostaglandins; moreover, NSAIDs exert gastrointestinal and 
cardiovascular complications that would preclude their chronic use. Thus, the ideal target 
should regulate the production of several pro-inflammatory factors, and its pharmacological 
manipulation should only attenuate (and not eliminate) the microglial inflammatory response. 
NADPH oxidase enzyme appears to fit this description. This plasma membrane enzyme is the 
principal producer of extracellular superoxide, and microglia are the primary cells in the CNS 
that express it. NADPH oxidase not only represents the primary ROS-producing enzyme 
during neuroinflammation, but it also regulates (via an autocrine manner) further release of 
several pro-inflammatory factors from microglia, including PGE2 and TNF?, (Qin et al., 
2004; Wang et al., 2004). Additionally, several environmental toxins that are associated with 
PD (such as MPTP, rotenone, and paraquat) or proteins that are released by injured 
dopaminergic neurons (including ?-synuclein, neuromelanin, and µ-calpain) activate NAPDH 
oxidase, thereby resulting in neurodegeneration (Gao et al., 2003a; Gao et al., 2003b; 
Levesque et al., 2010; Wu et al., 2005; Zhang et al., 2005; Zhang et al., 2011). Accordingly, 
both genetically ablating and pharmacologically inhibiting NADPH oxidase protects mice 
from MPTP, LPS, and paraquat-induced nigral dopaminergic degeneration (Gao et al., 2011a; 
Purisai et al., 2007; Wu et al., 2003). The putative role of NADPH oxidase in the pathology 
of PD is also supported by the finding that the ventral midbrain of PD patients exhibits high 
levels of this enzyme (Wu et al., 2003). 
 
2.5.6. Astroglia 
Astroglia are perhaps the most abundant cell  type in the CNS (or are at  least  on par 
with the number of neurons), and they ubiquitously tile the brain parenchyma without 
overlapping their domains. Based on their morphology, the two principal subtypes of 
astroglia are protoplasmic (in the gray matter) and fibrous (in the white matter). With their 
finely branched processes, protoplasmic astroglia envelop virtually every synapse within the 
CNS, whereas fibrous astroglia envelop the majority of the nodes of Ranvier, and both 
subtypes are in contact with the BBB. Astroglia exert multiple functions, including the 
regulation of blood flow, participation in the BBB structure, and maintenance of ion, pH, and 
nutrient homeostasis, all of which are critical for synaptic function (Sofroniew and Vinters, 
2010). Astroglia also strongly affect synaptic transmission by regulating the concentration of 
neurotransmitters and their metabolites and (together with the pre- and post-synaptic neurons) 
form the so-called tripartite synapse. Additionally, astroglia respond to virtually every CNS 
insult (e.g., infection, brain trauma, and neurodegeneration) with molecular and 
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morphological changes in what is referred to as reactive astrogliosis (Sofroniew, 2009). This 
is a gradual process that evolves from a mild form (with only increased expression of some 
markers without overlapping domains or proliferation) to a severe form in which proliferation 
and migration create scar tissue. The role of reactive astrogliosis in CNS pathology is highly 
complex, with evidence suggesting both beneficial and deleterious effects. For example, glial 
scar  tissue  interferes  with  axonal  growth,  whereas  it  hampers  the  propagation  of  tissue  
damage by isolating local inflammation. Thus, the role of reactive astrogliosis in the 
development of various CNS disorders is both context-dependent and tightly regulated by the 
microenvironment. 
 
2.5.7. Astroglia in PD 
Despite  the  notion  that  signs  of  reactive  astrogliosis  appear  in  virtually  every  CNS  
disorder, the astroglia in postmortem PD brains show no clear phenotypic changes (Mirza et 
al., 2000; Song et al., 2009). Indeed, only Damier and colleagues (1993) observed a 1.7-fold 
increase in GPx-positive cells, which they considered to be astroglia, in the SN of PD brains. 
Additionally, the brains of patients with multiple-system atrophy, progressive supranuclear 
palsy, or cortical basal degeneration display signs of reactive astrogliosis (Song et al., 2009). 
Likewise, the parkinsonism-inducing toxin MPTP causes reactive astrogliosis in the SN and 
STR of both mice and cats (Kohutnicka et al., 1998; Otto and Unsicker, 1994; Schneider and 
Denaro, 1988). Lastly, Aponso and colleagues (2008) observed astrogenesis in the STR of 
rats that were infused with 6-OHDA. 
The study of the role of astroglia in PD is only in its infancy, and this is likely due to 
their limited changes in the disease, which may be interpreted as either toxic or beneficial 
(Fig. 2). For example, it has been long known that the conversion of MPTP to its toxic form 
MPP+ by MAO-B occurs in astroglia (Ransom et al., 1987). MAO-B may have a causative 
role in the disease, as the increase in its activity is positively correlated with the degree of 
dopaminergic neuron loss in the SN of PD brains (Mandel et al., 2003). Moreover, the 
overexpression of MAO-B in the astroglia of adult transgenic mice induces several features 
of PD, including SN degeneration, activation of microglia, and behavioral impairment 
(Mallajosyula et al., 2008). Astroglia may exert a proinflammatory action, as (for example) 
LPS induces the release from these cells of soluble factors that cause toxicity in dopaminergic 
neurons in a mesencephalic culture (McNaught and Jenner, 1999). Similarly, the production 
of interferon gamma (IFN?) by lymphocytes upon systemic inflammation activates astroglia 
through its receptor and triggers the release of factors that are toxic in SH-SY5Y cells 
(Hashioka et al., 2009). Interestingly, IFN? receptors are present only on astroglia, and their 
expression is increased in PD brains (Hashioka et al., 2009; Hashioka et al., 2010). 
Additionally, the activation of astroglia seems to follow the activation of microglia, thereby 
resulting in an amplification of the inflammatory response. In support of this hypothesis, 
Kohutnicka and colleagues (1998) demonstrated that astrogliosis in the SN and STR occurs 
one day after the activation of microglia within these same areas. Accordingly, prostaglandin 
E 2 (PGE2), a pro-inflammatory cytokine that is released by activated microglia, induces the 
proliferation of primary astroglial cultures (Zhang et al., 2009a). Conversely, astroglia may 
stimulate the proliferation of microglia by releasing macrophage colony-stimulating factor 
(Henze et al., 2005; Saijo et al., 2009). Lastly, cytokines such as TNF? and interleukin 1? 
(IL-1?) induce both the expression of pro-inflammatory factors including iNOS and Ncf2, 
 27 
and the release of NO, which is toxic to a neuronal cell line (Saijo et al., 2009). Interestingly, 
the authors also demonstrated that the down-regulation of Nurr1 (which is associated with 
late-onset familial PD) in microglia and astroglia markedly enhances nigral dopaminergic 
neurodegeneration following an intranigral injection of either LPS or the A30P mutant of ?-
syn in mice. In addition, human ?-syn (and the mutant forms in particular) up-regulate 
inflammatory mediators such as, intracellular adhesion molecule 1 (ICAM-1) and IL-6 in 
astroglia (Klegeris et al., 2006). Moreover, the selective overexpression of the human A53T 
mutant ?-syn in astroglia of mice causes parkinsonian-like behavior with a loss of nigral 
dopaminergic neurons and neuroinflammation (Gu et al., 2010). This astroglial ?-syn 
pathology may have clinical relevance, as PD brains exhibit ?-syn accumulation in their 
astroglia (Braak et al., 2007). Moreover, Lee and colleagues (2010) demonstrated that ?-syn 
released from neurons can be endocytosed by astroglia, causing an inflammatory response in 
these cells. 
Astroglia, however, may support the survival of both healthy and degenerating 
neurons by releasing anti-oxidants and trophic factors, while removing extracellular toxic 
molecules (Fig. 2). For example, the removal of neurotransmitters such as glutamate from the 
synaptic cleft may mitigate the over-activation of the neuronal receptors that cause 
excitotoxicity (Seifert et al., 2006). Moreover, the removal of growth factor precursors (e.g., 
pro-BDNF), which are known to activate pathways that cause degeneration, may improve 
neuronal survival (Bergami et al., 2008). Alternatively, astroglia promote survival by 
releasing several factors. For example, GSH is an important anti-oxidant molecule that is 
released exclusively by these cells in the CNS (Hirrlinger et al., 2002). Interestingly, the 
synthesis of GSH is indirectly linked to DJ-1, which is associated with early-onset PD and is 
expressed primarily in astroglia, where it down-regulates their pro-inflammatory action 
(Bandopadhyay et al., 2004; Waak et al., 2009). Additionally, astroglia release anti-
inflammatory factors such as hydrogen sulfide (H2S), which McGeer´s group found to reduce 
LPS-induced inflammation and neurodegeneration (Lee et al., 2009). Furthermore, the same 
group recently reported that astroglia can synthesize and release the neurotransmitter ?-
aminobutyric acid (GABA), which inhibits the microglial inflammatory response (Lee et al., 
2011). Lastly, astroglia are an important source of many trophic factors that clearly exert pro-
survival effects on neurons. For example, glial-derived neurotrophic factor (GDNF) and 
mesencephalic astrocyte-derived neurotrophic factor (MANF), which protect dopaminergic 
neurons in animal models of PD, were initially isolated from astroglia (Lin et al., 1993; 
Petrova et al., 2003). Accordingly, Langan and colleagues (1995) demonstrated that astroglia 
that migrated to the STR of hemiparkinsonian rats produce multiple growth factors, including 
nerve growth factor (NGF). 
 
2.5.8. Astroglia as targets for the treatment of PD 
Despite their vast potential, to date, only a limited number of studies have targeted 
astroglia  in  developing  new  treatments  for  PD.  One  strategy  would  be  to  potentiate  the  
astroglial release of protective factors such as anti-inflammatory molecules, antioxidants, and 
growth factors. For example, the selective astroglial overexpression of the transcription factor 
Nrf2, which induces the expression of antioxidant enzymes, renders mice markedly resistant 
to MPTP toxicity (Chen et al., 2009). Additionally, the administration of H2S, an antioxidant 
factor that is released by astroglia, prevented—and even restored—the nigral dopaminergic 
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degeneration caused by either rotenone or 6-OHDA in rats (Hu et al., 2010). Moreover, a few 
studies revealed that ex vivo engineered astroglia, which deliver growth factors such as 
BDNF and GDNF, when grafted into the STR of rats that are unilaterally lesioned with 6-
OHDA prevents—and even restored—the damage to the nigral dopaminergic system 
(Cunningham and Su, 2002; Yoshimoto et al., 1995). Other researchers found that several 
drugs, including apomorphine (a dopamine D1/D2 receptor agonist), valproic acid, and 
memantine may protect degenerating neurons by stimulating the production of growth factors 
such as NGF and GDNF in astroglia (Chen et al., 2006; Ohta et al., 2000; Wu et al., 2009). 
Alternatively, enhancing the removal of extracellular toxic molecules by astroglia may lead 
to a neuroprotective therapy. For instance, Colton and colleagues (2010) found several 
compounds that strongly increased the uptake of glutamate in astroglial cultures by inducing 
the  expression  of  the  glial  glutamate  transporter  EAAT2  might  provide  protection  from  
excitotoxic neurodegeneration. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Hypothesized communication network between glial cells and dopaminergic neurons during 
neuroinflammation. Peripheral infections (or LPS exposure) evokes the release of pro-inflammatory factors 
from  Kupffer  cells  of  the  liver  and  other  immune  cells  into  the  blood  stream.  Some  of  these  factors  (TNF?,  
IFN?, IL-1?, etc.) cross the BBB and shift microglia from resting to an active state. Also, central infections (or 
LPS exposure) cause microglia to express several pro-inflammatory enzymes (iNOS, COX-2, etc.) mostly 
through the NF-kB signaling pathway. Upon activation, microglia release an array of factors that are toxic to 
dopaminergic neurons. In turn, degenerating neurons leak intracellular proteins (?-syn, neuromelanin, MPP-3, 
HMGB1, µ-calpain) that enhance the activation of microglia (over-activation), developing a self-sustained 
cycle. In addition, activated microglia, by releasing chemokines, induce the migration of peripheral immune 
cells (lymphocytes) and other microglial cells to the focal point of neuroinflammation boosting the process. 
Astroglia also sense some of the factors released by microglia (PGE2, TNF? and IL-1?) causing an astrogliosis 
reaction, in which anti-inflammatory molecules (GABA, H2S) and/or pro-inflammatory factors (TNF?, MCSF1) 
are released. Astroglia can also directly affect neurons by releasing pro-survival molecules (GFs and GSH) 
and/or toxic factors (MPP+, NO, TNF?). Additionally, astroglia remove from the extracellular space several 
potential neurotoxic molecules that are leaked or released by neurons (pro-BDNF, ?-syn, dopamine, glutamate). 
Lastly, environmental and experimental neurotoxins (e.g.: 6-OHDA and MPTP) could also initiate this complex 
communication network by directly damaging dopaminergic neurons, which in turn would leak pro-
inflammatory molecules. These molecules would then activate microglia to start the self-sustained 
neuroinflammatory process. GFs, growth factors; GSH, glutathione; IFN?, interferon ?; IL-1?, interleukin 1?; 
iNOS, inducible nitric oxide synthase; LPS, lipopolysaccharide; MCSF1, macrophage colony stimulating factor 
1; NO, nitric oxide; PGE2, prostaglandin E 2; TNF?, tumor necrosis factor ?.  
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3. AIMS OF THE STUDY 
 
The purpose of this study was to investigate the putative neuroprotective mechanisms of 
various compounds in models of dopaminergic neurodegeneration in vitro. 
The more specific aims were the following: 
? To investigate various forms of programmed cell death in the 6-OHDA-induced 
neuronal degeneration. (I) 
? To investigate the effects of quercetin and other dietary antioxidants on 6-OHDA-
induced dopaminergic neurodegeneration. (II-IV) 
? To investigate the role of glia in the neuroprotective action of amantadine. (V) 
Roman numbers refer to the original publications or manuscript on which this thesis is based 
on. 
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4. MATERIALS AND METHODS 
4.1 Cell cultures 
 
4.1.1 Cell lines 
 
4.1.1.1 Human dopaminergic neuroblastoma cells (SH-SY5Y) (I-III) 
The SH-SY5Y cell line is the third subclone of a neuroblastoma cell line (SK-N-SH) 
that was established from a bone marrow biopsy of a metastatic tumor. Due to their 
expression of tyrosine hydroxylase (TH), dopamine ?-hydroxylase, and dopamine transporter 
(DAT), SH-SY5Y cells are often used to mimic dopaminergic cells (Hong-rong et al., 2010). 
The cells were maintained in Dulbecco´s modified Eagle’s medium (DMEM)/Ham’s F12 
(1:1) supplemented with 15% heat-inactivated fetal bovine serum (FBS), 2 mM L-glutamine, 
1% non-essential amino acids and 200 U/ml penicillin and 200 µg/ml streptomycin (all 
purchased from Gibco BRL, UK). For plating and weekly passaging, the cells were washed 
with warm 0.1 M phosphate buffer saline (PBS) containing 1 mM EDTA and then detached 
with EDTA-free 0.25% trypsin in 0.1 M PBS. The culture medium was replaced every 3-4 
days. 
 
4.1.1.2 Rat microglial cells (HAPI) (V) 
HAPI cells are highly aggressive proliferating immortalized (HAPI) cells that were 
isolated from 3-day-old rat brains and exhibit a uniquely microglial phenotype 
(Cheepsunthorn et al., 2001). The cells were cultured in DMEM containing 10% heat 
inactivated FBS, 1 g/L glucose, 50 U/mL penicillin, and 50 µg/mL streptomycin. For plating 
and splitting (on every second day), the cells were washed with warm 0.1 M PBS and then 
detached with 0.25% trypsin containing 1 mM EDTA in 0.1 M PBS (Gibco BRL, UK). 
 
4.1.2 Primary cultures from rat brain (V) 
 
4.1.2.1 Mesencephalic neuron-glia cultures 
Primary neuron-glia mixed cultures were prepared by gentle trituration of the 
midbrain of 14-day-old Fisher 344 rat embryos (Gao et al., 2002c). The maintenance and 
treatment of the neuron-glia cultures is described in detail in (V). 
 
4.1.2.2 Neuron-enriched and neuron-astroglia cultures 
Both neuron-enriched and neuron-astroglia cultures were derived from neuron-glia 
cultures by either adding arabinofuranosyl cytidine or L-leucine methyl ester to block the 
growth of microglia and astroglia or solely microglia, respectively (Gao et al., 2002a). A 
detailed description of the culture technique is provided in (V). 
 
4.1.2.3 Mixed-glia and microglia-enriched cultures 
Primary mixed-glia cultures were obtained from the trituration of 1-3–day-old Fisher 
344 rat brains (Gao et al., 2002c). Primary microglia-enriched cultures were prepared from 
the cells that were shaken off from mixed-glia cultures two weeks after seeding. The detailed 
protocol is provided in (V). 
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4.1.2.4 Reconstituted neuron-microglia cultures 
To reconstitute neuron-microglia cultures, a microglia-enriched suspension was added 
to neuron-enriched cultures at a ratio of 1:10 (Gao et al., 2002c). The detailed protocol is 
provided in (V). 
 
4.2 Cell viability assays 
 
4.2.1 Lactate dehydrogenase (LDH) release (I-III) 
LDH is a stable cytosolic enzyme that is promptly released when the plasma 
membrane is damaged and is therefore commonly used as a measure of nonviable cells. LDH 
release was measured using the fluorometric method that is included in the CytoTox-ONE 
Kit (Promega, Madison, WI, USA) according to the manufacturer’s instruction and as 
described in (III). The data are expressed as a percentage of control after the subtraction of 
background fluorescence that was measured from the medium alone. 
 
4.2.2 Metabolic activity (I-III) 
Water-soluble 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) 
(Sigma–Aldrich, St. Louis, MO, USA) is reduced in the perinuclear vesicles of viable cells to 
its water-insoluble formazan product by dehydrogenases or flavin oxidases (Liu et al., 1997). 
MTT reduction was used as a measurean index of viable cells that were present in the 
cultures according to the protocol that is presented in (III) and in (Supino, 1995). 
 
4.2.3 [3H]Dopamine uptake (V) 
Due to the high expression of DAT in dopaminergic neurons, the rate of 
[3H]dopamine uptake is proportional to the number of functional neurons (Gao et al., 2002c). 
Because [3H]dopamine is also taken up by glia (Takeda et al., 2002), the results were 
corrected by the non-neuronal uptake using mazindol (see below).  
After two washes with warm Krebs-Ringer buffer [containing (in mM): 16 sodium 
phosphate, 119 NaCl, 4.7 KCl, 1.8 CaCl2, 1.2 MgSO4, 1.3 EDTA, and 5.6 glucose; pH 7], the 
cells were incubated with 1 µM [3H]dopamine and 1 µM dopamine (both purchased from 
Sigma–Aldrich) in warm Krebs-Ringer buffer for 20 min at 37ºC. Subsequently, the cells 
were washed three times with ice-cold Krebs-Ringer buffer and lysed with 1 M NaOH. 
Radioactivity was measured by liquid scintillation counting using a Beckman Tri-carb 2900 
TR liquid scintillation counter (Fullerton, CA). Non-neuronal [3H]dopamine uptake was 
measured  by  incubating  some  of  the  samples  of  each  treatment  with  mazindol  (10  ?M)  (a  
selective inhibitor of neuronal dopamine uptake) and subtracted. 
 
4.2.4 Immunocytochemistry for TH (V) 
TH+ cells were used to quantify dopaminergic neurons in primary cell cultures (Gao 
et al., 2002c). The cells were incubated with primary antibody (1:10000; rabbit anti-TH from 
Chemicon International Inc., Billerica, MA, USA) at 4°C overnight, followed by incubation 
with the secondary antibody (1:230; goat biotinylated labeled anti-rabbit from Vector 
Laboratories, Burlingame, CA, USA) for 1 h at room temperature (RT). Subsequently, the 
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cells were incubated with ABC reagent (Vector Laboratories, Inc., Burlingame, CA, USA) 
for 1 h at RT and then stained using 3,3’-diaminobenzidine (Sigma–Aldrich, St. Louis, MO, 
USA). A more detailed protocol is provided in (V). 
 
4.3 Other biochemical assays 
 
4.3.1 Caspase-3-like activity (I-III) 
Caspase-3-like activity was measured by monitoring the cleavage of a fluorogenic 
substrate that is specific for caspase-3 and 7 (Acetyl-Asp-Glu-Val-Aps-7-amino-4-methyl 
coumarin, Ac-DEVD-AMC) and leads to the release of the fluorochrome AMC (Mañáková et 
al., 2005). The fluorescent signal intensity is directly proportional to the amount of AMC that 
is released into the medium. A detailed protocol is provided in (III). The data are expressed as 
the release of AMC in pmol/min per mg of total protein content. 
 
4.3.2 Interference of polyphenols with AMC 
All of the polyphenols and AMC stock solutions (at 100 mM and 20 mM, 
respectively) were prepared in DMSO and stored at -21°C. The highest concentration of 
DMSO used (0.25%) did not interfere with AMC fluorescence. To assay the interference of 
various polyphenols with AMC fluorescence, various concentrations of the tested compounds 
were prepared in a mixture of 1:1 lysis buffer (10 mM Tris, 130 mM NaCl, 1% TritonX-100, 
10 mM NaH2PO4,  and  10  mM  Na2HPO4, pH 7.5) and assay buffer (20 mM HEPES, 10% 
glycerol,  and  2  mM DTT,  pH 7.5)  containing  30  µM AMC at  RT.  Immediately  thereafter,  
fluorescence was measured using a 96-well plate fluorescence reader (Varioskan, Thermo, 
Waltham, MA, USA) with excitation and emission wavelengths of 370 nm and 445 nm, 
respectively. To evaluate the intrinsic absorbance of the various compounds, we followed the 
same procedure described above in the absence of AMC. Noteworthy, none of the 
compounds exhibited intrinsic fluorescence when excited at 370 nm. 
 
4.3.3 TNF? and PGE2 (V) 
The  quantification  of  TNF? and  PGE2 that was released into the medium was 
performed following the manufacturer´s instructions of enzyme-linked immunosorbent assay 
(ELISA) kits from R&D Systems (Minneapolis, MN, USA) and Cayman Chemical Company 
(Ann Arbor, MI, USA), respectively, according to the manufacturer´s instructions. 
 
4.3.4 RT-PCR (V) 
RNA was extracted from mixed-glia cultures using the QIAshredder followed by the 
RNeasy Mini kit (both from Qiagen, Valencia, CA, USA). The RNA was reverse transcribed 
with oligo-dT primers (Sigma-Aldrich, St. Louis, MO, USA) (Wu et al., 2009). Real-time 
PCR was performed to amplify GDNF and GAPDH mRNA as described in (V). The level of 
GDNF mRNA was normalized to GAPDH mRNA. The normalized values from the non-
treated groups were set to 100%. 
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4.3.5 Chromatin immunoprecipitation (ChIP) (V) 
A ChIP assay was performed to measure the amount of acetylated histone H3 (Ac-
H3) that was bound to the GDNF promoter region as described in (V) (Wu et al., 2009). Ac-
H3 binds to the DNA of a specific gene and relaxes the chromatin structure, thereby allowing 
gene transcription (Xu et al., 2005a). 
 
4.4 Drugs 
 
4.4.1 Drugs used to model dopaminergic neuron degeneration in vitro 
We used 6-OHDA and MPP+ (both from Sigma–Aldrich) to induce the selective 
degeneration of dopaminergic neurons due to their high affinity for DAT, which is 
abundantly and preferentially expressed in dopaminergic neurons (Kitamura et al., 2000). In 
addition, we used LPS (from E. coli 0111:B4, Calbiochem, Darmstadt, Germany), which, in 
the presence of microglia, triggers the release of pro-inflammatory factors that, in turn, cause 
the selective loss of dopaminergic neurons due to their higher sensitivity to oxidative stress 
(Gao et al., 2011b). The 6-OHDA stock solution (10 mM) was prepared in water containing 
0.2% ascorbic acid immediately prior to each experiment and was protected from light and 
kept on ice during use. The MPP+ stock solution (10 mM) was prepared in water and stored at 
–80ºC. The LPS stock solution (2.5 mg/ml) was prepared in water as follows: after the 
addition of water, the vial was extensively vortexed and incubated for 15 min at 37 ºC four 
times (for a total incubation time about 60 min) and then stored at –80ºC. 
 
4.4.2 Drugs used to counteract toxin-induced neurodegeneration 
The following compounds were used to study the modalities of drug-induced toxicity: 
BOC-Asp(OMe)-FMK (BAF, a pan-caspase inhibitor), 3-methyladenine (3-MA, an 
autophagy inhibitor), pepstatin A (Pep A, a cathepsin D inhibitor), cycloheximide (CHX, a 
protein synthesis inhibitor), and necrostatin-1 (Nec-1, a necroptosis inhibitor) (all purchased 
from Sigma–Aldrich, St. Louis, MO, USA, except for Nec-1, which was purchased from 
Bachem,  Bubendorf,  Switzerland).  The  stock  solutions  of  BAF  (20  mM),  Nec-1  (50  mM),  
CHX (1 mM), and PepA (20 mM) were prepared in DMSO and were stored at – 20ºC. 3-MA 
(4 mM) was dissolved in the medium just immediately prior to each experiment by sonication 
in a water bath at 60ºC for 20 min. 
The drugs quercetin, resveratrol, EGCG, curcumin, amantadine, and minocycline (all 
of which were purchased from Sigma–Aldrich, except for curcumin, which was provided by 
Lihel, Espoo, Finland) were tested for their putative neuroprotective properties. The stock 
solutions of quercetin (100 mM), resveratrol (100 mM), EGCG (100 mM), curcumin (100 
mM), and minocycline (50 mM) were prepared in DMSO, and the stock solution of 
amantadine (10 mM) was prepared in water. All of these stock solutions were stored at –20ºC 
until use. 
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4.5 Statistics (I-V) 
Values are expressed as means ± SEM. Statistical analyses were performed with one-
way ANOVA followed by a Tukey test (unless otherwise stated) using GraphPad Prism 4.0 
or 5.0 software (GraphPad Software, Inc., San Diego, CA, USA). Differences with a p-value 
less than 0.05 were considered significant.  
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5. RESULTS 
 
5.1 6-OHDA induces a variety of PCD modalities 
6-OHDA is a toxin that is widely used both in vitro and in vivo to model the 
degeneration of dopaminergic neurons that occurs in PD. Most studies have focused on 
apoptosis as the 6-OHDA–induced form of PCD and have neglected other, caspase-
independent PCD pathways. Here, we investigated both caspase-dependent and caspase-
independent PCD pathways that are induced by 6-OHDA in SH-SY5Y cells. 
 
5.1.1 6-OHDA induces a time-dependent toxicity in SH-SY5Y cells (III) 
6-OHDA decreased the metabolic activity of SH-SY5Y cells primarily within the first 
15 h of exposure, whereas the primary loss of membrane integrity was observed after 15-24 h 
of  exposure  (Fig.  3A).  This  underscores  the  different  sensitivity  of  these  two  methods,  
wherein toxin-induced changes in metabolic activity precede changes in membrane integrity. 
 
5.1.2 6-OHDA induces apoptosis in SH-SY5Y cells (I, unpublished) 
Among the various apoptotic markers, activation of caspase-3, DNA fragmentation, 
and nuclear condensation are the most reliable, as they represent a point-of-no-return for the 
apoptotic machinery. In our cellular model, 6-OHDA significantly induced caspase-3–like 
activity (Fig. 3B), nuclear condensation and DNA fragmentation (I). 
6-OHDA–induced caspase-3–like activity was markedly decreased after 6 h of 
exposure, and this is likely because apoptotic cells in vitro ultimately lose membrane integrity 
and thereby undergo secondary necrosis. Importantly, the presence of BAF, a pan-caspase 
inhibitor, efficiently blocked 6-OHDA–induced caspase-3–like activity and DNA 
fragmentation but only partially protected SH-SY5Y cells (by approximately 15-20%) (I and 
III). 
 
Figure 3. Time-dependent 6-OHDA-induced toxicity. SH-SY5Y cells were exposed to 6-OHDA (100 µM in A, 
75 µM in B) for various time points (0 - 48 h). Cell survival was assayed as index of metabolic activity (left Y 
axis), while cell death was assayed as index of LDH release (right Y axis) (A). Caspase-3-like activity was 
assayed as an index of AMC cleaved form the substrate AC-DEVD-AMC (B). Data represent the mean ± SEM 
of four independent experiments. Statistics: *p < 0.05; ***p < 0.001 vs 0 h. (With permission of the publisher 
from Ossola et al., 2008). 
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5.1.3 6-OHDA induces caspase-independent PCD in SH-SY5Y cells (I, 
unpublished) 
To assess the presence of caspase-independent PCD pathways in our 
neurodegeneration model, we tested various PCD inhibitors. Figure 4 illustrates that 3-MA, a 
specific inhibitor of autophagy, partially inhibited 6-OHDA–induced toxicity. We next tested 
CHX, which inhibits protein synthesis prevents PCD pathways that require de novo proteins, 
for example, paraptosis (Asare et al., 2008; Schneider et al., 2004; Sperandio et al., 2000). 
Indeed, CHX significantly reduced 6-OHDA–induced toxicity (Fig. 4) in a caspase-3–
independent manner, as CHX was without effect on 6-OHDA–induced caspase-3–like 
activity (I). On the other hand, neither PepA (a cathepsin D inhibitor) nor Nec-1 (a specific 
necroptosis inhibitor) provided the cells with significant protection from 6-OHDA (Fig. 4). 
Because often the inhibition of necropoptosis causes a cell to die via apoptosis, we inhibited 
simultaneously these two cell death modalities by incubating SH-SY5Y cells with Nec-1 and 
BAF (apoptosis inhibitor). Unfortunately, these combined treatment failed to show an 
additive neuronal protection from 6-OHDA toxicity (data not shown). 
 
Figure 4. 6-OHDA induces caspase-independent PCD in SH-SY5Y cells. SH-SY5Y cells were incubated with 3-
methyladenine (3-MA, 1 mM) and necrostatin-1 (Nec-1, 100 µM) for 1h, or cycloheximide (CHX, 1 µM) and 
pepstatin A (PepA, 200 µM) for 24 h before the exposure to 6-OHDA (100 µM) for additional 24 h. Cell 
survival was assayed as index of metabolic activity (A), while cell death was assayed as index of LDH release 
(B). Data represent the mean ± SEM of four independent experiments. Statistics: #p < 0.05; ##p < 0.01; ###p < 
0.001 vs 6-OHDA alone. 
 
5.1.4 Minocycline inhibits both caspase-dependent and caspase–independent 
PCD (I) 
The growing body of evidence supporting the presence of caspase-independent PCD 
pathways in neurodegenerative models and diseases prompted us to investigate the action of 
drugs such as minocycline on these less-studied pathways. 
First, we found that minocycline prevented 6-OHDA–induced caspase-3–like activity, 
DNA fragmentation,  and  nuclear  condensation,  all  of  which  are  hallmarks  of  apoptosis  (I).  
Second, we investigated the action of minocycline on alternative PCD pathways by 
comparing its effect with the effect of both BAF, a caspase-dependent PCD blocker, and 
CHX, a PCD blocker that is caspase-independent in our system (I). Interestingly, minocycline 
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conferred significantly better protection against the 6-OHDA–induced loss of metabolic 
activity  in  SH-SY5Y  cells  than  either  BAF  or  CHX  alone  (Fig.  5A).  A  similar  trend  
(although not reaching statistical significance) was seen using the membrane integrity assay 
(Fig. 5B). When the cells were incubated with both BAF and CHX, we observed significantly 
enhanced neuroprotection, thereby confirming the presence of both PCD pathways in 6-
OHDA toxicity. The combination of minocycline and BAF caused significantly increased cell 
membrane integrity when compared to minocycline alone but failed to increase metabolic 
activity (Fig. 5). Lastly, the combination of minocycline and CHX failed to augment the 
protective action of minocycline alone. 
 
Figure 5. Minocycline inhibits both caspase-dependent and –independent PCD. SH-SY5Y cells were 
preincubated with either minocycline (Min, 10 ?M) or cycloheximide (CHX, 1 ?M) 24 h prior to the exposure 
to 6-OHDA (100 µM) for 24 h, while BAF (50 ?M) was incubated only 15 min before the use of 6-OHDA. Cell 
survival was assayed as index of metabolic activity (A), while cell death was assayed as index of LDH release 
(B). Data represent the mean ± SEM of at least four independent experiments. Statistics: *p < 0.05; **p < 0.01; 
***p < 0.001 vs indicated treatment. 
 
5.2 The effects of dietary antioxidants on 6-OHDA toxicity 
Due to the putative benefits of anti-oxidant therapy in PD, we investigated the 
neuroprotective properties of various dietary molecules such as quercetin, resveratrol, EGCG, 
and curcumin, all of which have anti-oxidative properties. 
 
5.2.1 Time-dependent effects of quercetin on SH-SY5Y cell survival (III, 
unpublished) 
The presence of quercetin (at 50 µM) prevented the 6-OHDA–induced reduction in 
metabolic activity and increased LDH release (Fig. 6A and B). However, this protection 
progressively diminished over time until it was lost at 48 h. This most likely resulted from the 
compound toxicity that primarily peaked after 24 h. Hosokawa and colleagues (Hosokawa et 
al., 1990) revealed that quercetin inhibits the expression of Hsp70, and this, in turn, promotes 
cell survival by preventing lysosomal membrane permeabilization (LMP) (Nylandsted et al., 
2004). Thus, we investigated whether the inhibition of specific lysosomal proteases by PepA 
(a cathepsin D inhibitor) could affect quercetin-induced cell death. Indeed, PepA significantly 
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reduced quercetin toxicity after 48 h of exposure, suggesting that quercetin caused cell death 
at least partially by inducing the release of lysosomal enzymes (Fig. 6C). This dual, opposing 
action of quercetin (early protection and late toxicity) that is observed in vitro may partially 
explain the lack of robust protection in vivo. Indeed, as assessed by behavioral and 
biochemical methods, quercetin failed to provide clear protection to rats that were unilaterally 
lesioned with 6-OHDA (II and III). 
 
Figure 6. Time-dependent effect of quercetin on SH-SY5Y cells survival. SH-SY5Y cells were preincubated with 
quercetin (Q, 50 ?M) 24 h prior to the exposure to 6-OHDA (100 µM, 6 – 48 h) (A and B). Otherwise, SH-
SY5Y cells were preincubated with pepstatin A (PepA) for 1 h before the exposure to Q (100 µM, 48 h) (C). 
Cell  survival  was  assayed as  index of  metabolic  activity  (A and C),  while  cell  death  was  assayed as  index of  
LDH release (B). Data represent the mean ± SEM of at least four independent experiments. Statistics: ###p < 
0.001 Q vs control at corresponding time; **p < 0.01 and ***p < 0.001 vs 6-OHDA alone at corresponding time 
(A and B), or vs Q alone (C). 
 
5.2.2 The effects of polyphenols on SH-SY5Y cell survival (unpublished) 
In addition to quercetin, we investigated the putative protective effects of other 
polyphenolic compounds such as resveratrol, EGCG, and curcumin. Figure 7 reveals that 
only curcumin (10 µM) prevented 6-OHDA–induced toxicity, whereas resveratrol (10 µM) 
and EGCG (100 µM) both failed to provide protection. Noteworthy a higher concentration of 
curcumin (50 µM) markedly enhanced the metabolic loss caused by 6-OHDA (Fig. 7A), and 
this concentration also caused extensive toxicity (measured by both MTT and LDH assays) 
on  its  own  (data  not  illustrated).  Similarly,  a  higher  concentration  of  resveratrol  (100  µM)  
significantly enhanced 6-OHDA–induced cell death; however, it exerted only limited toxicity 
on its own (data not illustrated). Lastly, none of the concentrations of EGCG that we tested 
(1, 10, 50, or 100 µM) caused any signs of toxicity either alone or in combination with 6-
OHDA (data not illustrated).  
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Figure 7. Effect of polyphenols on SH-SHY5Y cells survival. SH-SY5Y cells were preincubated with resveratrol 
(Res, 10 ?M), epigallocatechin gallate (EGCG, 100 µM), and curcumin (Curc) 24 h prior to the exposure to 6-
OHDA (100 µM) for 24 h. Cell survival was assayed as index of metabolic activity (A), while cell death was 
assayed as index of LDH release (B). Data represent the mean ± SEM of at least four independent experiments. 
Statistics: **p < 0.01 and ***p < 0.001 vs 6-OHDA alone. 
 
5.2.3 Methodological pitfalls: interference of polyphenols with AMC 
(unpublished) 
AMC is commonly conjugated to substrates and used to assess the activity of 
proteolytic enzymes such as caspases. Upon cleavage of the substrate, AMC is released, and 
its fluorescence, which is measurable with the excitation and emission wavelengths of 330-
390 nm and 340-460 nm, respectively, allows one to calculate enzymatic activity. Thus, a 
compound that interferes with AMC fluorescence may lead to an erroneous conclusion 
regarding its effects on enzymatic activity. An AMC interference test (Fig. 8A) revealed that 
curcumin significantly reduced AMC fluorescence at concentrations as low as 10 µM. 
Moreover, both quercetin and minocycline interfered with fluorescence at concentrations of ? 
50 µM, whereas resveratrol decreased AMC fluorescence only at 100 µM. Finally, EGCG 
exhibited no interference with AMC fluorescence at any of the concentrations that were 
tested. To investigate this phenomenon, we measured the absorbance of 100 µM of the 
different compounds alone between 300 and 550 nm (Fig. 8B). The absorbance spectrum 
revealed that curcumin strongly absorbed light at the emission wavelength of AMC (445 nm), 
thereby explaining its interference. In contrast, quercetin and minocycline absorbed light only 
marginally at 445 nm, and their interference may be due to their absorbance at the excitation 
wavelength of AMC (370 nm). Concordantly, the relatively low interference by resveratrol 
and  EGCG  may  result  from  their  lack  of  absorption  at  either  the  excitation  or  emission  
wavelength of AMC. 
 
Figure 8. Interference of polyphenols with AMC. Dose-dependent interference of various polyphenols with 
AMC (30 µM) fluorescence (A). Data represent the means ± SEM of at least four independent experiments. 
Statistics: *, p < 0.05; ***, p < 0.001 vs AMC alone. Absorbance spectrum of 100 µM of the various 
poliphenolic compounds between 300 and 550 nm (B). 
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5.3 The neuroprotective mechanisms of amantadine 
Both microglia and astroglia have been strongly linked to the pathophysiology of 
various neurodegenerative disorders such as PD and AD. Thus, developing drugs that target 
glia may be a successful approach for delaying or even stopping the onset and/or progression 
of neurodegenerative diseases. Here, we investigated the neuroprotective properties of 
amantadine and its action on glia. 
 
5.3.1 Amantadine protects dopaminergic neurons from MPP+ and LPS (V) 
We used primary midbrain neuron-glia mixed cultures (containing neurons, microglia, 
and astroglia) that were incubated with either MPP+ or LPS, both of which cause the selective 
and progressive degeneration of dopaminergic neurons. To assess the protective potency of 
amantadine, we measured its effect on dopaminergic cell survival as assayed by dopamine 
uptake and the number of TH+ cells. Cells that were exposed to amantadine alone exhibited a 
significant increase in both dopamine uptake and TH+ cells  at  a  concentration  of  30  µM  
(Table 1). Additionally, both viability assays showed that amantadine (? 30 µM) prevented 
both MPP+- and LPS-induced toxicity. 
 
Table 1: Amantadine protects dopamine 
neurons against MPP+ and 
lipopolysaccharide (LPS). Primary 
mesencephalic neuron-glia cultures were 
incubated with amantadine (Ama) 48 h before 
the exposure to either MPP+ (0.25 µM) or LPS 
(10 ng/ml) for additional 7 days. Dopamine 
neurons survival was assayed by measuring 
dopamine uptake and tyrosine hydroxylase 
positive (TH+) cells. Statistics: *p < 0.05 and 
***p < 0.001 vs control; #p< 0.05, ## p < 
0.01, and ###p < 0.001 vs either MPP+ or LPS 
alone. 
 
 
5.3.2 The role of glia in the 
neuroprotective action of 
amantadine (V) 
To investigate the role of glia 
in the protective effect of amantadine, 
we used primary cultures that were 
composed of various combinations of 
neurons, microglia, and astroglia (Fig. 9). In neuron-enriched cultures, amantadine prevented 
MPP+ toxicity by 1.4-fold compared to the toxin alone. More robust protection (1.9-fold) was 
conferred by amantadine in neuron-microglia cultures that were stimulated with LPS. In 
neuron-astroglia cultures, amantadine exerted the strongest protection against MPP+, with 
2.3-folds compared to the toxin alone. Moreover, in neuron-astroglia cultures, but not in 
either neuron-enriched or neuron-microglia cultures, amantadine alone significantly increased 
dopamine uptake compared to control. Altogether, these data underscore a clear role of both 
microglia and astroglia in the neuroprotective action of amantadine. 
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Figure 9. The role of glia in the neuroprotective action of amantadine. Various primary cultures were exposed 
to  amantadine  (Ama,  30  µM)  48  h  prior  to  stimulation  with  MPP+ (0.25µM, for 7 days) or 24 h prior to 
stimulation with LPS (10 ng/ml, for 4 days). The following cultures were used: neuron-enriched (N), neuron-
astroglia (N-A), and reconstituted neuron-microglia coculture (N-M). Dopamine neurons survival was assayed 
by measuring  dopamine  uptake.  Data  are  expressed  as  either  % of  control  (grey  columns)  or  % of  MPP+ and 
LPS alone (white columns). Data represent the mean ± SEM of at least five independent experiments. Statistics: 
***<0.001 vs control; ## <0.01; ### <0.001, vs MPP+ or LPS alone.  
 
5.3.3 The anti-inflammatory action of amantadine (V) 
To study the direct action of amantadine on microglia, we tested the drug in primary 
microglia-enriched cultures. After stimulation with LPS, microglia release an array of 
proinflammatory factors such as TNF? and PGE2, which, in turn, cause the degeneration of 
dopamine neurons. The presence of amantadine prevented the LPS-induced release of both 
TNF? and PGE2 in a dose-dependent manner (Fig. 10). In addition, we found that amantadine 
prevented the activation of NADPH oxidase in HAPI cells, which are immortalized rat 
microglia (V). Noteworthy NADPH oxidase is the principal superoxide-producing enzyme in 
all phagocytes, including microglia. 
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Figure 10. The anti-inflammatory action of amantadine. Microglia-enriched cultures were exposed to 
amantadine (Ama) 30 min prior to stimulation with LPS (10 ng/ml). Supernatants were collected at 3 h for 
TNF? (A) and at 24 h for PGE2 (B), protein concentrations were measured by ELISA kits. Data represent the 
mean ± SEM of at least five independent experiments. Statistics: #<0.05; ##<0.01 vs LPS alone. (With 
permission of the publisher from Ossola et al., 2011). 
 
5.3.4 Amantadine induces the expression of GDNF in astroglia (V) 
Because of the importance of astroglia in the neuroprotective action of amantadine, 
we investigated whether this drug can induce the expression of growth factors such as GDNF 
in astroglia. We used a primary mixed-glia culture that was composed of approximately 90% 
astroglia and 10% microglia because in this system astroglia are more responsive to drugs 
(see section 6.1.1 in Methodological considerations below). Indeed, amantadine significantly 
increased the level of GDNF mRNA in mixed-glia cultures after 48 and 72 h (Figure 11A). 
To confirm this action of amantadine, we measured the amount of Ac-H3 that interacted with 
the promoter region of GNDF using the ChIP assay in mixed-glia cultures. Ac-H3 binds to 
the DNA of specific genes and relaxes the chromatin structure, thereby allowing gene 
transcription. The ChIP assay showed that amantadine significantly increased the amount of 
Ac-H3 that was bound to the GDNF promoter in mixed-glia cultures after 12 h (Figure 11B). 
 
Figure 11. Amantadine induces the expression of GDNF in astroglia. Mixed glia-cultures, containing about 
90% astroglia and 10% microglia, were exposed to amantadine (30 µM) for various time points. Total RNA was 
extracted, reverse transcribed, and used for quantitative real-time PCR (A). Results are expressed as % of non-
treated cells at corresponding time after normalization with GAPDH. Data represent the mean ± SEM of at least 
six independent experiments. Statistics: *<0.05; **<0.01 vs control. The level of acetylated histone 3(Ac-
Histone H3) bound to GDNF promoter was measured by ChIP assay and normalized against the total DNA 
input (B). Data represent the mean ± SEM of three independent experiments. Statistics: ***<0.001 vs 0 h. (With 
permission of the publisher from Ossola et al., 2011).  
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6. DISCUSSION 
 
6.1 Methodological considerations 
 
6.1.1 Cell cultures 
SH-SY5Y cells are highly enriched in neuron-like cells; however, after continued 
passaging this culture exhibits changes in cell morphology that include shortened neurites and 
larger somas. In our study, we carefully detached the SH-SY5Y cells during the weekly 
splitting, and we used cells that were subcultured between 17 and 30 times to minimize 
variability. Moreover, SH-SY5Y cell suspensions were thoroughly dissociated by gentle 
pipetting to reduce the number of cell clusters that this cell line tends to form. 
To obtain primary neuron-enriched cultures, the timing and concentration of 
arabinofuranosyl cytidine addition is critical and should be empirically determined. Because 
of their high rate of replication, we aimed to keep the relative number of astroglia at ? 10% in 
our neuron-enriched cultures. 
To assess GDNF expression in astroglia (Fig. 11A, V) we used a mixed-glia culture 
(containing about 10% microglia and 90% astroglia), as our preliminary studies showed that 
the use of L-leucine methyl ester to eliminate microglia affected the production of growth 
factors in astroglia. Moreover, astroglia are believed to be the primary source of growth 
factors in the CNS (Darlington, 2005). 
 
6.1.2 Preparation of drug solutions 
3-MA is best prepared fresh, but its dissolution in water requires heating and 
sonication. In our study, we dissolved 3-MA in the medium by sonicating the solution for 10-
20 min in a water-bath at 60ºC. 
The  stock  solution  of  PepA  (20  mM)  in  DMSO  was  diluted  to  the  final  working  
concentration with medium. However, after the dilution, I noted the presence of crystals that 
failed to completely dissolve even with sonication and heating. This incomplete dissolution 
of PepA may partially explain its non-significant protection against 6-OHDA. 
 
6.1.3 Various assays  
LDH release. The CytoTox-One kit that was used in this study shows inconsistencies 
in the presence of high concentrations of the enzyme LDH, for example, when cells are lysed 
to measure the maximum releasable LDH. Therefore, I expressed the data as a percentage of 
control rather than as a percentage of maximum toxicity. Because LDH activity is usually 
measured in medium that contains the tested compounds, the enzymatic activity might be 
influenced  by  these  molecules.  Thus,  LDH  activity  should  be  tested  in  the  presence  of  the  
compounds in a cell-free system to assess the possible interference. 
Metabolic activity. The reduction of MTT is a result of several cellular functions such 
as endocytosis, enzyme activity, and exocytosis (Liu et al., 1997). Thus, a compound that 
affects any of these cellular functions might cause a misinterpretation of the data. In addition, 
absorption of the MTT product is dependent on the pH of the solution (Plumb et al., 1989). 
Thus, compounds that modify the pH of the medium might lead to an erroneous assessment 
of viability. 
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The  concomitant  use  of  LDH  release  and  MTT  assays  by  a  carefully  observing  
researcher allowed us to compensate for the limits and pitfalls of these two methods, thereby 
providing a more reliable conclusion. As mentioned in section 5.1.1, MTT detects toxin-
induced cell viability loss prior to LDH release assay. Conversely, changes in LDH release 
are often more sensitive than the MTT test at detecting the protective effect of a compound, 
thereby showing stronger and longer protection. 
Caspase-3–like activity. As mentioned in section 4.3.1, we used a caspase substrate 
that was conjugated with the fluorophore AMC. Figure 8 shows that polyphenols interfere 
with AMC fluorescence to various extents. This interference led us to overestimate the direct 
inhibitory effect of quercetin on caspase-3 activity in (III). In fact, in that study, we exposed 
recombinant caspase-3 in the presence of its substrate and quercetin. Thus, the observed 
decrease in caspase-3 activity was most likely due to quercetin quenching AMC’s 
fluorescence rather than a reflection of true enzymatic inhibition. However, the reduced 6-
OHDA–induced caspase-3–like activity that we detected in SH-SY5Y cells that were pre-
incubated with quercetin can primarily be attributed to truly reduced enzymatic activity. This 
conclusion is based on two observations: 1) in the interference test, 50 µM quercetin reduced 
AMC fluorescence by approximately 50%, whereas the same concentration of quercetin 
reduced caspase-3–like activity by approximately 82%; and 2) to measure caspase-3–like 
activity, the quercetin-containing medium was removed and the cells were rinsed with PBS 
before being lysed in approximately 150-200 µl of lysis buffer. Consequently, the amount of 
intracellular quercetin was diluted by at least an order of magnitude, thereby decreasing its 
interference effect on AMC fluorescence. In study (I), the minocycline-induced inhibition of 
caspase-3–like activity can be considered a true effect, as the interference is minimal at the 
concentration of minocycline that was used (10 µM). 
 
6.2 The role of non-apoptotic PCD in 6-OHDA-induced toxicity 
In our study, 6-OHDA caused the degeneration of SH-SY5Y cells in a dose- and 
time-dependent manner (II). Moreover, the toxin decreased metabolic activity before the cells 
lost  their  membrane  integrity,  which  suggests  an  intracellular  cascade  of  events  that  led  to  
cell death (Figure 3A). Indeed, the increase in caspase-3-like activity and the DNA and nuclei 
fragmentation confirmed the activation of apoptosis by 6-OHDA in our cultures (Fig. 3B, and 
I). However, the blockade of caspase-dependent cell death by BAF, which inhibited the 
toxin-induced caspase-3–like activation and DNA fragmentation, only marginally protected 
SH-SY5Y cells (II). Similarly, Lee and colleagues (2007) observed that a pan-caspase 
inhibitor fails to completely protect PC12 cells from toxicity by 6-OHDA. Therefore, these 
data suggest that, in addition to apoptosis, 6-OHDA induces cell death through other 
mechanisms. Indeed, the partial inhibition of de novo protein synthesis by cycloheximide 
(CHX) significantly protected the cell cultures without affecting caspase-3–like activity (Fig. 
4 and I). Moreover, the blockade of apoptosis by BAF in the presence of CHX resulted in a 
significantly higher protection from the toxin (Fig. 5). Thus, together these data suggest that 
6-OHDA induced a PCD modality that is additional to and independent from apoptosis. 
Because there is some evidence indicating that CHX may regulate autophagy (Abeliovich et 
al., 2000), we tested whether autophagic cell death plays a role in this neurodegenerative 
model. Indeed, 3-MA, a selective inhibitor of autophagosome formation, significantly 
protected cells from death by 6-OHDA (Fig. 4). This is consistent with the results from Chu´s 
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groups demonstrating that both MPP+ and 6-OHDA induce an autophagic stress state in SH-
SY5Y cells, which seems to be (at least partially) the cause of cell death (Dagda et al., 2008; 
Zhu et al., 2007). These data seem to disagree with the notion of autophagy as a pro-survival 
process. However, we cannot exclude the possibility that the toxic accumulation of 
autophagic vacuoles (which is prevented by 3-MA to exert neuroprotection) may be the result 
of 6-OHDA–induced impairment of autophagosome clearance. We hypothesized that this 
impairment may derive from the toxin-induced loss of lysosomal membrane integrity, which 
may cause a reduction in autophagic vacuole clearance efficiency and the release of 
potentially deleterious enzymes such as cysteine cathepsin proteases. Indeed, the inhibition of 
these lysosomal enzymes partially prevents the toxicity of 6-OHDA in both rat striatum and 
PC12 cells (Lee et al., 2007; Xu et al., 2005b). Unfortunately, in our system, the inhibition of 
cathepsin D (the principal lysosomal enzyme that retains its activity at cytosolic pH) by PepA 
failed to significantly protect (Fig. 4, and see Methodological considerations section 6.1.2). 
Another form of PCD modality that has been recently described is necroptosis, which 
is morphologically similar to necrosis, with an early loss of membrane integrity and an 
absence of nuclear fragmentation, but is tightly regulated (Degterev et al., 2008). We 
investigated whether this PCD modality plays a role in our neurodegenerative model by using 
Nec-1, a selective inhibitor of necroptosis. Unfortunately, pre-incubating SH-SY5Y cells 
with Nec-1 failed to confer significant protection against 6-OHDA–induced cell loss (Fig. 4). 
Lastly, the fact that 6-OHDA–induced cell death with limited DNA and nuclear 
fragmentation (I), the absence of the effect of Nec-1 (Fig. 4), and more importantly the 
protective action of CHX (Fig. 4), suggest the possible presence of paraptosis (Sperandio et 
al., 2000). This hypothesis led us to investigate the presence of cytoplasmic paraptotic 
vacuoles by confocal imaging (I). Indeed, several SH-SY5Y cells exposed to 6-OHDA for 6 
h displayed the presence of large cytoplasmic vacuoles in the absence of nuclear 
fragmentation (I). However, to confirm that 6-OHDA induces also paraptosis, a more detailed 
imaging study with the use of electron microscopy is recommendable. 
Our study demonstrates that the neurotoxin 6-OHDA induces several PCD modalities, 
including apoptosis, autophagy, lysosomal membrane permeabilization, and, perhaps, 
paraptosis. Therefore, each of these cell death modalities should be considered when testing 
the neuroprotective properties of various compounds. For example, we found that 
minocycline, a second-generation tetracycline with protective properties in several animal 
models, prevented 6-OHDA–induced toxicity by inhibiting both caspase-dependent and 
caspase-independent PCD (I). Specifically, minocycline conferred significantly greater 
protection  than  either  BAF  or  CHX  alone,  whereas  the  combination  of  BAF  and  CHX  
showed similar or slightly better protection than minocycline alone (Fig. 5). Lastly, the 
combination of minocycline and BAF enhanced the protective effects of minocycline, thereby 
suggesting that minocycline only partially blocked caspase-dependent death. However, CHX 
failed to enhance the protective potency of minocycline, suggesting a possible saturation of 
the overlapping mechanisms of action the drugs. 
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6.3 Dietary antioxidants in neuroprotection 
Regardless of which PCD modalities are involved in the cell death, 6-OHDA causes 
their activation by inducing oxidative stress. In fact, this toxin gives rise to ROS by oxidation 
as a byproduct of its metabolism, which can occur either intracellularly or extracellularly 
(Blum et al., 2001). Thus, this neurodegeneration model is particularly suitable for the study 
of the putative protective effect of antioxidants such as some dietary compounds. 
Several studies claimed that quercetin, one of the most widely studied flavonoids, 
exerts potent neuroprotection in both in vitro and in vivo models of various neurological 
disorders (Ossola et al., 2009). However, we found that quercetin failed to consistently 
prevent 6-OHDA–induced behavioral impairment and dopaminergic neurodegeneration in 
unilaterally lesioned rats (II). Moreover, we found that this flavonoid protected SH-SY5Y 
cells from 6-OHDA–induced cell loss at 50 µM and caused toxicity at 100 µM (II). In a more 
systematic study, we found that quercetin also conferred protection in a narrow concentration 
range and in a narrow time window. More specifically, in the early stages of 6-OHDA–
induced toxicity, quercetin strongly protected the cell cultures, as shown by measuring cell 
viability and caspase-3–like activity (Fig. 6 and III). However, in later stages, the flavonoid 
failed to prevent 6-OHDA–induced cell loss and the increase of caspase-3–like activity (Fig. 
6 and III). This was likely because quercetin by itself caused a decrease in cell viability and 
increased capase-3–like activity after prolonged exposure (Fig. 6 and III). This is consistent 
with a report demonstrating that after scavenging free radicals, quercetin is converted to an 
ortho-quinone (QQ), which may be harmful to cultures (Metodiewa et al., 1999). QQ seems 
to be responsible for the reduction of many antioxidant cellular systems such as glutathione 
(GSH) (Metodiewa et al., 1999), glutathione S-transferase activity, CAT activity, SOD 
activity and total antioxidant capacity (Robaszkiewicz et al., 2007). Moreover, QQ is highly 
reactive towards thiols, which can lead to a loss of protein function (Boots et al., 2003). For 
example, Hosokawa and colleagues (1990) demonstrated that quercetin inhibits the 
expression of Hsp70, a protein that stabilizes lysosomal membranes (Nylandsted et al., 2004). 
Accordingly, the delayed toxicity of quercetin that we observed in our system seemed to 
result from a lysosomal leakage of cathepsin D, as its inhibition by PepA partially prevented 
cell loss (Fig. 6C). Together, these data suggest that the neuroprotective properties of 
quercetin (and perhaps other polyphenols) might have been overestimated by in vitro studies 
that investigated only the early stages of various neurodegenerative models. 
Resveratrol, another polyphenol that is believed to partially explain the “French 
paradox” because of its high level in red wines, has drawn attention for its putative 
neuroprotective properties (see section 2.4.2). However, in our study, this compound failed to 
prevent the loss of SH-SY5Y cells by 6-OHDA (Fig. 7). Similarly, Filomeni and colleagues 
(2010) failed to observe a reduction of rotenone-induced apoptosis in SH-SY5Y cells. In our 
system, higher concentrations of resveratrol (10-100 µM) tended to enhance the toxic effect 
of 6-OHDA, whereas it induced only modest cell loss when incubated alone. This is 
consistent with a report demonstrating that the enzyme tyrosinase (which is expressed in SH-
SY5Y cells as well as in the SN) in the presence of resveratrol produces 
dihydrobenzothiazine, a potent neurotoxin (Vauzour et al., 2007). Thus, the finding that 
resveratrol exerts neuroprotection in only in a limited number of in vitro systems (and usually 
at high concentrations) and that it may cause neuronal toxicity casts doubts on its potential 
use in preventing PD. 
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Several studies revealed that EGCG, the most abundant flavonoid in tea, confers 
marked protection in various models of dopaminergic neurodegeneration (see section 2.4.3). 
Unexpectedly, in our hands, EGCG failed to prevent 6-OHDA–induced toxicity in SH-SY5Y 
cells at the concentrations that we tested (1-100 µM), which by themselves showed no 
toxicity (Fig. 7). This is in contradiction with two other studies that reported a protective 
effect of EGCG (at 0.1-10 µM) in the same cellular system exposed to 6-OHDA (Levites et 
al., 2002; Wang et al., 2009b). These discordant outcomes may partially result from 
differences in the cell medium composition, particularly the low amount of serum (2% versus 
15% in our experiments) that was used during drug exposure. 
Lastly, in the past few years, a considerable number of studies have shown that 
curcumin exerts beneficial effects in various models of dopaminergic neuron degeneration 
(see section 2.4.4). Accordingly, in our hands, curcumin (10 µM) prevented cell loss caused 
by 6-OHDA in SH-SY5Y cells. This is consistent with a very recent study reporting that 
curcumin inhibited 6-OHDA–induced ROS and up-regulated pro-apoptotic proteins in this 
same cell type (Jaisin et al., 2011). However, higher concentrations (50 µM) of curcumin 
alone caused a marked degeneration of SH-SY5Y cells and enhanced the toxicity of 6-OHDA 
(Fig. 7). Consistent with this finding, Lantto and colleagues (2009) showed that curcumin (? 
25 µM) evokes a loss in the viability of SH-SY5Y cells that is accompanied by an increased 
level of p53, a protein marker of cellular stress. 
Our data on the neuroprotective properties of dietary antioxidants highlight the fact 
that these molecules failed to show consistency in preventing oxidative stress-induced cell 
loss in various cellular systems, as in the cases of resveratrol and EGCG. However, even in 
the presence of neuroprotection, as with quercetin and curcumin, the therapeutic 
concentration range is narrow, and it seems to be restricted to a narrow time window. More 
importantly, as discussed above, the concentrations required to obtain neuroprotection are 
generally several fold higher than what these compounds can reach in the target tissues. 
Lastly, the bioactivity of the metabolites of these polyphenols, which are the principal forms 
that  are  present  in  humans,  largely  remains  unstudied,  with  the  exception  of  a  few  reports  
showing a reduction of activity in comparison with the parent compound. 
 
6.4 Glia as targets for PD treatment: focus on amantadine 
To study the role of glia both in the degeneration of dopaminergic neurons and in 
neuroprotection, we used rat midbrain neuron-glia cultures containing neurons (50% of the 
total cells, of which 2-4% were TH+ cells), astroglia (40%), and microglia (10%). We tested 
the neuroprotective properties of drugs against selective and progressive dopaminergic 
neurodegeneration that resulted from the exposure of the primary cell cultures to either MPP+ 
or LPS. 
Amantadine is an FDA-approved antiviral drug that is commonly used in combination 
with L-DOPA to reduce motor deficit in PD patients (Diaz and Waters, 2009). Evidence 
suggests  that  amantadine  may  also  delay  the  onset  and  severity  of  PD-related  dementia  
(Inzelberg et al., 2006; Vale, 2008), thereby hinting that this drug, in addition to relieving 
symptoms, may also confer neuroprotection. For example, a retrospective study showed that 
parkinsonian patients treated with amantadine lived longer compared to untreated patients 
(Uitti et al., 1996). In addition, Rojas and colleagues (1992) demonstrated that amantadine 
partially prevents the degeneration of the terminals of dopaminergic neurons in the striatum 
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of MPTP-treated mice. In our study, we investigated the direct role of the various glial cell 
types and their cross-talk with neurons in the neuroprotective properties of amantadine by 
using midbrain primary cultures with various compositions of neurons, microglia, and 
astroglia. To model the neurodegeneration that occurs in PD, we exposed the various cell 
cultures to either MPP+ or  LPS,  which  cause  the  selective  and  progressive  loss  of  
dopaminergic neurons. Amantadine prevented the loss of dopamine uptake and TH+ cells 
caused by either MPP+ or LPS in a dose-dependent manner in neuron-glia cultures (Table 1). 
Next, by using different culture compositions (e.g., neuron-enriched, neuron-microglia, and 
neuron-astroglia cultures), we found that amantadine protected dopaminergic neurons by 
acting on both astroglia and microglia (Fig. 9). Because LPS toxicity is dependent on the 
activation of microglia (which, in turn, release an array of pro-inflammatory factors), we 
investigated the direct action of amantadine on these cells. Indeed, amantadine inhibited LPS-
induced pro-inflammatory factors such as TNF? and PGE2 in microglia-enriched cultures and 
blocked the activation of NADPH oxidase in HAPI cells (rat microglia cell line), the primary 
source of extracellular ROS (Fig. 10 and V). These data are in agreement with a recent report 
suggesting that amantadine decreases the pro-inflammatory properties of activated 
macrophages and redirects them toward a more anti-inflammatory phenotype (Roman et al., 
2009). 
To explore why the presence of astroglia markedly enhanced the protective effect of 
amantadine, we investigated the expression profile of neurotrofic factors. Since the seminal 
discovery of the first member of this family by Levi Montalcini and Hamburger (1949), 
named nerve growth factor, this category of proteins has drawn great interest for their action 
of neurons. For example most these growth factors induce neuronal differentiation, neurites 
outgrowth, and are usual potent pro-survival stimuli. Among them, glial cell line-derived 
neurotrofic factor (GDNF) is the most studied for its protective and regenerative effects on 
dopaminergic neurons (Rangasamy et al., 2010). Thus, we decided to measure the action of 
amantadine on the expression of GDNF in astroglia. Treating mixed-glia cultures (containing 
90% astroglia and 10% microglia) with amantadine caused a time-dependent increase in 
GDNF mRNA as well  as an increased level of the Ac-H3–bound GDNF promoter (Fig.  11 
and V). This finding is consistent with previous reports showing that amantadine increases 
the expression of GDNF in glioma cells (C6) and BDNF in the rat cerebral cortex (Caumont 
et al., 2006; Rogoz et al., 2008). Importantly, the concentrations of amantadine that were used 
in this study may be clinically relevant, as they are likely reached in the human brain by 
chronic oral administration as discussed in (V). 
These data highlight the potential therapeutic benefit of molecules such as amantadine 
and others that target glia in neurodegeneration and (as described in section 2.5) may affect 
the pathophysiology of PD. In fact, the inhibition of microglia activation and the subsequent 
reduction of the release of cytokines, ROS, and RNS may delay or even halt the progression 
of neuronal loss. In particular, suppressing NADPH oxidase activity holds great therapeutic 
potential by limiting the microglial release of the factors with the highest neurotoxicity. In 
addition, small molecules that efficiently penetrate the BBB and enhance the beneficial 
properties of astroglia (including their production of growth factors) may protect or even 
regenerate disease-injured neurons. In conclusion, I advocate searching for compounds that—
like amantadine—can inhibit microglia toxicity while at the same time enhancing astroglia-
induced pro-survival actions. Alternatively, a combination of multiple compounds may help 
to target both glial cell types and neurons.  
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7. Conclusions 
The aim of this study was to investigate the role of various PCD modalities, oxidative stress, 
and glial cells both in the degeneration of dopaminergic cells and in the neuroprotective 
properties of various compounds. The principal results can be summarized as follows: 
? Data from the study of 6-OHDA toxicity suggest that, in addition to apoptosis, other 
forms of PCD such as autophagic stress, lysosomal membrane permeabilization, and, 
perhaps, paraptosis contribute to the degeneration of SH-SY5Y cells. Moreover, these 
caspase-independent PCDs may play a role in the neuroprotective actions of drugs 
(e.g., minocycline). Thus, alternative PCD modalities should be considered as 
potential targets for delaying or even stopping neuronal loss. 
 
? The polyphenols that were tested in our study either failed to prevent 6-OHDA–
induced oxidative stress and cell death, as in the cases of resveratrol and EGCG, or 
their protection was restricted to a narrow concentration range and a narrow time 
window,  as  in  the  cases  of  quercetin  and  curcumin.  This,  together  with  the  marked  
unfavorable pharmacokinetic profiles of all of these compounds, casts doubt on the 
efficacy of this kind of anti-oxidant therapy in the treatment of PD. 
 
? Data from the study on amantadine suggest that treatments that inhibit the release of 
neurotoxic factors from overactivated microglia and enhance the cytoprotective 
properties of astroglia hold great potential for the therapy of neurodegenerative 
disorders. More specifically, the blockage of microglial NADPH oxidase that leads to 
a reduction of pro-inflammatory factors and ROS/RNS, and the increased release of 
growth factors from astroglia may prevent neuronal loss or even promote neuronal 
regeneration. 
 
In conclusion, this study suggests that preventing the production of oxidative species (for 
example, by inhibiting microglial NADPH oxidase) rather than dampening ROS and RNS 
with anti-oxidants is a promising approach to halting the neurodegeneration process. 
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